{"content":"<li class=\"n-box-item date-title\" data-end=\"1576040399\" data-start=\"1575954000\" data-txt=\"Monday, December 23, 2019\">Tuesday, December 10, 2019</li><li class=\"n-box-item sa-box-item\" data-id=\"3525382\" data-ts=\"1576017148\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525382-gmre-gme-olli-and-play-among-after-hour-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GMRE, GME, OLLI and PLAY among after hour movers</a></h4><ul><li><strong>Gainers: </strong><a href='https://seekingalpha.com/symbol/ASPU' title='Aspen Group, Inc.'>ASPU</a> <font color=\"green\">+13.1%</font>. <a href='https://seekingalpha.com/symbol/OLLI' title='Ollie&#39;s Bargain Outlet Holdings, Inc.'>OLLI</a> <font color=\"green\">+10.3%</font>. <a href='https://seekingalpha.com/symbol/YUMA' title='Yuma Energy, Inc.'>YUMA</a> <font color=\"green\">+5.6%</font>. <a href='https://seekingalpha.com/symbol/PAM' title='Pampa Energía S.A.'>PAM</a> <font color=\"green\">+3.2%</font>. <a href='https://seekingalpha.com/symbol/PLAY' title='Dave & Buster&#39;s Entertainment, Inc.'>PLAY</a> <font color=\"green\">+2.5%</font>.</li><li><strong>Losers: </strong><a href='https://seekingalpha.com/symbol/ITRM' title='Iterum Therapeutics plc'>ITRM</a> <font color=\"red\">-39.8%</font>. <a href='https://seekingalpha.com/symbol/GME' title='GameStop Corp.'>GME</a> <font color=\"red\">-15.4%. </font><a href='https://seekingalpha.com/symbol/AQST' title='Aquestive Therapeutics, Inc.'>AQST</a> <font color=\"red\">-14.8%</font>. <a href='https://seekingalpha.com/symbol/GMRE' title='Global Medical REIT Inc.'>GMRE</a> <font color=\"red\">-6.5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525382\" data-linked=\"GMRE, GME, OLLI and PLAY among after hour movers\" data-tweet=\"$ASPU $OLLI $YUMA - GMRE, GME, OLLI and PLAY among after hour movers https://seekingalpha.com/news/3525382-gmre-gme-olli-and-play-among-after-hour-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3525382-gmre-gme-olli-and-play-among-after-hour-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525380\" data-ts=\"1576016891\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHH\" target=\"_blank\">CHH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525380-choice-hotelsplus-4-amid-move-to-midcap-400\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Choice Hotels +4% amid move to MidCap 400</a></h4><ul>    <li>Choice Hotels (NYSE:<a href='https://seekingalpha.com/symbol/CHH' title='Choice Hotels International, Inc.'>CHH</a>) is <font color=\"green\">up 4%</font> after hours following news that it's moving into the S&amp;P <a href=\"https://us.spindices.com/documents/indexnews/announcements/20191210-1048359/1048359_6Choice4Plantronics46.pdf?force_download=true\" target=\"_blank\">MidCap 400 index</a>.</li>    <li>It's making that move to replace Plantronics (NYSE:<a href='https://seekingalpha.com/symbol/PLT' title='Plantronics, Inc.'>PLT</a>), which is moving down into the SmallCap 600.</li>    <li>And Plantronics is moving down to replace Vitamin Shoppe (NYSE:<a href='https://seekingalpha.com/symbol/VSI' title='Vitamin Shoppe, Inc.'>VSI</a>), which is about to be acquired by Franchise Group. Plantronics' market capitalization is more reflective of a small-cap than Choice, S&amp;P says.</li>    <li>The moves are effective prior to the open of trading on Tuesday, Dec. 17.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3525380\" data-linked=\"Choice Hotels +4% amid move to MidCap 400\" data-tweet=\"$CHH $CHH $PLT - Choice Hotels +4% amid move to MidCap 400 https://seekingalpha.com/news/3525380-choice-hotelsplus-4-amid-move-to-midcap-400?source=tweet\" data-url=\"https://seekingalpha.com/news/3525380-choice-hotelsplus-4-amid-move-to-midcap-400\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525372\" data-ts=\"1576015511\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZDGE\" target=\"_blank\">ZDGE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525372-app-suspension-hits-zedge-q1-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">App suspension hits Zedge Q1 results</a></h4><ul>   <li>Zedge (NYSEMKT:<a href='https://seekingalpha.com/symbol/ZDGE' title='Zedge, Inc.'>ZDGE</a>) saw revenues drop and operating losses widen in <a href=\"https://seekingalpha.com/news/3525300-zedge-reports-q1-results\" target=\"_blank\">fiscal Q1 results</a> after a buggy app hit the company's user numbers.</li>    <li>Monthly active users in the last 30 days dropped 14.2% to 29.7M; buggy code in a technology integration with a third-party ad partner caused Google Play to temporarily suspend the company's app and recommend an uninstall.</li>    <li>MAU was down 28.4% in well developed markets and dropped 4.6% in emerging markets.</li>    <li>Revenues fell nearly 15%, and operating loss grew to $745K from a year-ago loss of $581K.</li>    <li>Total installs rose 16.4% to 409M, paid subs increased 53% sequentially to 198,000, and average revenue per MAU was flat at $0.021.</li>    <li>Premium gross transaction value rose to $192,000, from a year-ago $41,000 and last quarter's $167,000.</li>    <li>Cash flow from operations was $352,000, down $569K Y/Y.</li>    <li>Shares are <font color=\"red\">down 10.5%</font> in light after-hours trading.</li>    <li><a href=\"https://seekingalpha.com/pr/17724394-zedge-announces-first-quarter-fiscal-2020-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3525372\" data-linked=\"App suspension hits Zedge Q1 results\" data-tweet=\"$ZDGE - App suspension hits Zedge Q1 results https://seekingalpha.com/news/3525372-app-suspension-hits-zedge-q1-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3525372-app-suspension-hits-zedge-q1-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:05 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525370\" data-ts=\"1576015347\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DBX\" target=\"_blank\">DBX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525370-dropboxminus-2_9-chief-customer-officer-resigns\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dropbox -2.9% as Chief Customer Officer resigns</a></h4><ul><li>Dropbox (NASDAQ:<a href='https://seekingalpha.com/symbol/DBX' title='Dropbox, Inc.'>DBX</a>) <a href=\"https://seekingalpha.com/filing/4730722\" target=\"_blank\">announces</a> that Chief Customer Officer Yamini Rangan will resign.</li><li>Rangan will remain on to help with the transition until January 3.</li><li>She will receive a transition payment of $500K.</li><li>DBX shares are <font color=\"red\">down 2.9%</font> after hours to $17.30.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525370\" data-linked=\"Dropbox -2.9% as Chief Customer Officer resigns\" data-tweet=\"$DBX - Dropbox -2.9% as Chief Customer Officer resigns https://seekingalpha.com/news/3525370-dropboxminus-2_9-chief-customer-officer-resigns?source=tweet\" data-url=\"https://seekingalpha.com/news/3525370-dropboxminus-2_9-chief-customer-officer-resigns\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525358\" data-ts=\"1576014758\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KIDS\" target=\"_blank\">KIDS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525358-orthopediatrics-readies-stock-offering-shares-down-3-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">OrthoPediatrics readies stock offering; shares down 3% after hours</a></h4><ul><li>OrthoPediatrics (NASDAQ:<a href='https://seekingalpha.com/symbol/KIDS' title='OrthoPediatrics Corp.'>KIDS</a>) <a href=\"https://seekingalpha.com/pr/17724452-orthopediatrics-corp-announces-proposed-public-offering-of-common-stock\" target=\"_blank\">launches </a>a public offering of common stock. Price, volume and terms have yet to be released. Shares down <font color=\"red\">3%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525358\" data-linked=\"OrthoPediatrics readies stock offering; shares down 3% after hours\" data-tweet=\"$KIDS - OrthoPediatrics readies stock offering; shares down 3% after hours https://seekingalpha.com/news/3525358-orthopediatrics-readies-stock-offering-shares-down-3-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3525358-orthopediatrics-readies-stock-offering-shares-down-3-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:52 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525356\" data-ts=\"1576014646\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MRNS\" target=\"_blank\">MRNS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525356-marinus-pharma-initiates-equity-offering-shares-down-7-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Marinus Pharma initiates equity offering; shares down 7% after hours</a></h4><ul><li>Marinus Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/MRNS' title='Marinus Pharmaceuticals, Inc.'>MRNS</a>) slips <font color=\"red\">7%</font> after hours in reaction to its announced <a href=\"https://seekingalpha.com/pr/17724448-marinus-pharmaceuticals-announces-proposed-public-offering-of-common-stock-and-concurrent\" target=\"_blank\">stock offering</a>. Price, volume and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525356\" data-linked=\"Marinus Pharma initiates equity offering; shares down 7% after hours\" data-tweet=\"$MRNS - Marinus Pharma initiates equity offering; shares down 7% after hours https://seekingalpha.com/news/3525356-marinus-pharma-initiates-equity-offering-shares-down-7-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3525356-marinus-pharma-initiates-equity-offering-shares-down-7-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525352\" data-ts=\"1576014248\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ITRM\" target=\"_blank\">ITRM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525352-iterums-sulopenem-misses-endpoint-in-ciai-study-shares-down-48-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Iterum&#39;s sulopenem misses endpoint in cIAI study; shares down 48% after hours</a></h4><ul><li>Iterum Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ITRM' title='Iterum Therapeutics plc'>ITRM</a>) <a href=\"https://seekingalpha.com/pr/17724392-iterum-therapeutics-announces-topline-results-from-phase-3-clinical-trial-of-oral-and-iv\" target=\"_blank\">announces </a>the results from a Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03358576?lead=iterum+therapeutics&amp;phase=2&amp;draw=2&amp;rank=1\" target=\"_blank\">SURE 3</a>, evaluating penem anti-infective sulopenem in patients complicated intra-abdominal infections (cIAI).</li><li>The trial (narrowly) missed the primary endpoint of clinical response at day 28 compared to ertapenem, thereby failing to demonstrate non-inferiority. Specifically, the 95% confidence interval required a lower limit of the difference in outcomes of no more than 10.0%. The results showed an interval of -10.3% to 1.0%.</li><li>On the safety front, the rates of treatment-related adverse events for sulopenem and ertapenem were 6.0% and 5.1%, respectively, with the most common being diarrhea, 4.5% and 2.4%, respectively. Serious adverse events were higher with sulopenem (7.5%) than ertapenem (3.6%) but the discontinuation rate was lower, 1.5% vs. 2.4%.</li><li>Topline data from another <a href=\"https://clinicaltrials.gov/ct2/show/NCT03357614?lead=iterum+therapeutics&amp;phase=2&amp;draw=2&amp;rank=2\" target=\"_blank\">Phase 3</a> should be available next quarter. If positive, the company intends to proceed with a U.S. marketing application.</li><li>Shares down <font color=\"red\">48%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525352\" data-linked=\"Iterum&#39;s sulopenem misses endpoint in cIAI study; shares down 48% after hours\" data-tweet=\"$ITRM - Iterum&#39;s sulopenem misses endpoint in cIAI study; shares down 48% after hours https://seekingalpha.com/news/3525352-iterums-sulopenem-misses-endpoint-in-ciai-study-shares-down-48-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3525352-iterums-sulopenem-misses-endpoint-in-ciai-study-shares-down-48-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:44 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525324\" data-ts=\"1576013022\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PI\" target=\"_blank\">PI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525324-impinj-plans-75m-private-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Impinj plans $75M private offering</a></h4><ul><li>Impinj (NASDAQ:<a href='https://seekingalpha.com/symbol/PI' title='Impinj, Inc.'>PI</a>)<a href=\"https://seekingalpha.com/pr/17724362-impinj-inc-announces-proposed-private-offering-of-75-million-of-convertible-senior-notes-due\" target=\"_blank\"> plans to offer</a> $75M of convertible senior notes due 2026 in a private offering.</li><li>The company expects to grant the initial purchasers a 13-day option to purchase up to $11.25M of additional notes.</li><li>Impinj plans to use a portion of the proceeds to cover its capped call transactions.</li><li>PI shares are<font color=\"red\"> down 4.1%</font> after hours to $29.57.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525324\" data-linked=\"Impinj plans $75M private offering\" data-tweet=\"$PI - Impinj plans $75M private offering https://seekingalpha.com/news/3525324-impinj-plans-75m-private-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3525324-impinj-plans-75m-private-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525318\" data-ts=\"1576012865\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CORV\" target=\"_blank\">CORV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525318-fda-advisory-committee-thumbs-down-on-correvios-brinavess-for-af\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA advisory committee thumbs down on Correvio&#39;s Brinavess for AF</a></h4><ul><li>The FDA's Cardiovascular and Renal Drugs Advisory Committee has voted 11-2 against approval of Correvio Pharma's (NASDAQ:<a href='https://seekingalpha.com/symbol/CORV' title='Correvio Pharma Corp.'>CORV</a>) Brinavess (vernakalant hydrochloride, IV) for the rapid conversion of recent onset atrial fibrillation &#40;AF&#41; in adults.</li><li>Shares are currently halted, but longs should expect a significant down move upon resumption of trade.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525318\" data-linked=\"FDA advisory committee thumbs down on Correvio&#39;s Brinavess for AF\" data-tweet=\"$CORV - FDA advisory committee thumbs down on Correvio&#39;s Brinavess for AF https://seekingalpha.com/news/3525318-fda-advisory-committee-thumbs-down-on-correvios-brinavess-for-af?source=tweet\" data-url=\"https://seekingalpha.com/news/3525318-fda-advisory-committee-thumbs-down-on-correvios-brinavess-for-af\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:21 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525317\" data-ts=\"1576012862\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLAY\" target=\"_blank\">PLAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525317-dave-bustersplus-3-after-guidance-satisfies\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dave &amp; Buster&#39;s +3% after guidance satisfies</a></h4><ul> <li>Dave &amp; Buster's Entertainment (NASDAQ:<a href='https://seekingalpha.com/symbol/PLAY' title='Dave & Buster&#39;s Entertainment, Inc.'>PLAY</a>) reports comparable sales fell 4.1% in Q3  to fall a bit short of the consensus expectation for a 4.0% decline. The decrease in comparable store sales was driven by a 4.6% decline in walk-in sales, which was partially offset by a 0.7% increase in special events sales. Comparable store sales decreased 3.9% in Amusements &amp; Other and 4.4% in Food &amp; Beverage.</li> <li>Adjusted EBITDA was down 13% to $39.8M during the quarter vs. $40.9M consensus.</li> <li>Looking ahead, D&amp;B sees full-year revenue of $1.347B to $1.354B vs. $1.338B to $1.359B prior view and $1.35B consensus.</li> <li>Shares of Dave &amp; Buster's are <font color=\"green\">up 2.55%</font> in AH trading to $41.00.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3525288-dave-and-amp-busters-eps-beats-0_03-beats-on-revenue\" target=\"_blank\">Dave &amp; Buster's EPS beats by $0.03, beats on revenue</a> (Dec. 10)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3525317\" data-linked=\"Dave &amp; Buster&#39;s +3% after guidance satisfies\" data-tweet=\"$PLAY - Dave &amp; Buster&#39;s +3% after guidance satisfies https://seekingalpha.com/news/3525317-dave-bustersplus-3-after-guidance-satisfies?source=tweet\" data-url=\"https://seekingalpha.com/news/3525317-dave-bustersplus-3-after-guidance-satisfies\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525311\" data-ts=\"1576012611\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OLLI\" target=\"_blank\">OLLI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525311-ollies-higher-after-earnings-topper\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ollie&#39;s higher after earnings topper</a></h4><ul>  <li>Ollie's Bargain Outlet Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/OLLI' title='Ollie&#39;s Bargain Outlet Holdings, Inc.'>OLLI</a>) is higher after comparable sales fall by 1.4% in <a href=\"https://seekingalpha.com/pr/17724378-ollie-s-bargain-outlet-holdings-inc-reports-third-quarter-fiscal-2019-financial-results\" target=\"_blank\">Q3</a> to miss the consensus estimate for a 1.1% drop, but the company's top line and bottom line both came in ahead of expectations.</li> <li>The company says margins improved slightly in the quarter as an increase in merchandise margin, partially offset by higher supply chain costs as a percentage of net sales</li>   <li>The retailer expects FY20 revenue of $1.419B to $1.43B vs. $1.43B and FY20 $1.95 to $2.00 vs. $1.99 consensus.</li> <li>Ollie's also disclosed the hiring of John Swygert as CEO following the death of Mark Butler.</li><li>Shares of Ollie's are up <font color=\"green\">12.19%</font> AH to $67.71.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3525311\" data-linked=\"Ollie&#39;s higher after earnings topper\" data-tweet=\"$OLLI - Ollie&#39;s higher after earnings topper https://seekingalpha.com/news/3525311-ollies-higher-after-earnings-topper?source=tweet\" data-url=\"https://seekingalpha.com/news/3525311-ollies-higher-after-earnings-topper\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525309\" data-ts=\"1576012551\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNTA\" target=\"_blank\">MNTA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525309-momenta-pharma-launches-200m-stock-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Momenta Pharma launches $200M stock offering</a></h4><ul><li>Momenta Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/MNTA' title='Momenta Pharmaceuticals, Inc.'>MNTA</a>) <a href=\"https://seekingalpha.com/pr/17724364-momenta-pharmaceuticals-announces-proposed-public-offering-of-common-stock\" target=\"_blank\">commences </a>a $200M public offering of common stock. Price, volume and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525309\" data-linked=\"Momenta Pharma launches $200M stock offering\" data-tweet=\"$MNTA - Momenta Pharma launches $200M stock offering https://seekingalpha.com/news/3525309-momenta-pharma-launches-200m-stock-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3525309-momenta-pharma-launches-200m-stock-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525298\" data-ts=\"1576012349\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GME\" target=\"_blank\">GME</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525298-gamestopminus-15-sales-evaporate\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GameStop -15% as sales evaporate</a></h4><ul> <li>Shares of GameStop (NYSE:<a href='https://seekingalpha.com/symbol/GME' title='GameStop Corp.'>GME</a>) slump after <a href=\"https://seekingalpha.com/pr/17724382-gamestop-reports-third-quarter-fiscal-2019-results-and-updates-fiscal-2019-guidance\" target=\"_blank\">Q3</a> comparable sales fell 23.2% vs. -13.4% consensus.</li> <li>New hardware sales fell 46% during the quarter with consumers waiting on the next generation console launches in 2020.  New software sales were down 33% as growth in Nintendo Switch software titles were more than offset by weaker title launches across other consoles. Accessories sales decreased 13%.</li> <li>Gross margin was 30.7% of sales vs. 30.0% consensus.</li> <li>Looking ahead, GameStop sees a comp sales decline in the high teens vs. low teens prior view. EPS of $0.10 to $0.20 is expected for the full year vs. $1.15 to $1.30 prior and $1.26 consensus.</li> <li>GME <font color=\"red\">-15.33%</font> AH to $5.51.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3525291-gamestop-eps-misses-0_66-misses-on-revenue\" target=\"_blank\">GameStop EPS misses by $0.66, misses on revenue</a> (Dec. 10)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3525298\" data-linked=\"GameStop -15% as sales evaporate\" data-tweet=\"$GME - GameStop -15% as sales evaporate https://seekingalpha.com/news/3525298-gamestopminus-15-sales-evaporate?source=tweet\" data-url=\"https://seekingalpha.com/news/3525298-gamestopminus-15-sales-evaporate\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>204&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525296\" data-ts=\"1576012253\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RCKT\" target=\"_blank\">RCKT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525296-rocket-pharma-down-5-after-hours-on-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rocket Pharma down 5% after hours on equity offering</a></h4><ul><li>Rocket Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/RCKT' title='Rocket Pharmaceuticals, Inc.'>RCKT</a>) slips <font color=\"red\">5%</font> after hours in reaction to its <a href=\"https://seekingalpha.com/pr/17724344-rocket-pharmaceuticals-announces-proposed-public-offering-of-common-stock\" target=\"_blank\">$75M public offering</a> of common stock. Price, volume and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525296\" data-linked=\"Rocket Pharma down 5% after hours on equity offering\" data-tweet=\"$RCKT - Rocket Pharma down 5% after hours on equity offering https://seekingalpha.com/news/3525296-rocket-pharma-down-5-after-hours-on-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3525296-rocket-pharma-down-5-after-hours-on-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:10 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525292\" data-ts=\"1576012161\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDGL\" target=\"_blank\">MDGL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525292-madrigal-launches-1_2m-share-stock-offering-current-investor\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Madrigal launches 1.2M-share stock offering by current investor</a></h4><ul><li>Madrigal Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/MDGL' title='Madrigal Pharmaceuticals, Inc.'>MDGL</a>) <a href=\"https://seekingalpha.com/pr/17724347-madrigal-pharmaceuticals-announces-secondary-offering-of-1200-000-shares-of-common-stock\" target=\"_blank\">commences </a>a 1.2M-share public offering of shares owned by funds affiliated with Bay City Capital, LLC. Price and terms have yet to be announced.</li><li>The company will not receive any proceeds from the sale.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525292\" data-linked=\"Madrigal launches 1.2M-share stock offering by current investor\" data-tweet=\"$MDGL - Madrigal launches 1.2M-share stock offering by current investor https://seekingalpha.com/news/3525292-madrigal-launches-1_2m-share-stock-offering-current-investor?source=tweet\" data-url=\"https://seekingalpha.com/news/3525292-madrigal-launches-1_2m-share-stock-offering-current-investor\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525289\" data-ts=\"1576012070\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OLLI\" target=\"_blank\">OLLI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525289-ollies-bargain-outlet-eps-beats-0_03-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ollie&#39;s Bargain Outlet EPS beats by $0.03, beats on revenue</a></h4><ul><li>Ollie's Bargain Outlet (NASDAQ:<a href='https://seekingalpha.com/symbol/OLLI' title='Ollie&#39;s Bargain Outlet Holdings, Inc.'>OLLI</a>): Q3 GAAP EPS of $0.41 <font color=\"green\">beats by $0.03</font>.</li><li>Revenue of $327.05M (+15.3% Y/Y) <font color=\"green\">beats by $4.49M</font>.</li><li>Shares <font color=\"green\">+12.02%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17724378-ollie-s-bargain-outlet-holdings-inc-reports-third-quarter-fiscal-2019-financial-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3525289\" data-linked=\"Ollie&#39;s Bargain Outlet EPS beats by $0.03, beats on revenue\" data-tweet=\"$OLLI - Ollie&#39;s Bargain Outlet EPS beats by $0.03, beats on revenue https://seekingalpha.com/news/3525289-ollies-bargain-outlet-eps-beats-0_03-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3525289-ollies-bargain-outlet-eps-beats-0_03-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525288\" data-ts=\"1576012044\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLAY\" target=\"_blank\">PLAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525288-dave-and-amp-busters-eps-beats-0_03-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dave &amp;amp; Buster&#39;s EPS beats by $0.03, beats on revenue</a></h4><ul><li>Dave &amp; Buster's (NASDAQ:<a href='https://seekingalpha.com/symbol/PLAY' title='Dave & Buster&#39;s Entertainment, Inc.'>PLAY</a>): Q3 Non-GAAP EPS of $0.10 <font color=\"green\">beats by $0.03</font>; GAAP EPS of $0.02 <font color=\"red\">misses by $0.04</font>.</li><li>Revenue of $299.4M (+6.1% Y/Y) <font color=\"green\">beats by $3.01M</font>.</li><li>Shares <font color=\"green\">+2%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17724380-dave-buster-s-achieves-6_1-revenue-growth-in-third-quarter\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3525288\" data-linked=\"Dave &amp;amp; Buster&#39;s EPS beats by $0.03, beats on revenue\" data-tweet=\"$PLAY - Dave &amp; Buster&#39;s EPS beats by $0.03, beats on revenue https://seekingalpha.com/news/3525288-dave-and-amp-busters-eps-beats-0_03-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3525288-dave-and-amp-busters-eps-beats-0_03-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:07 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525287\" data-ts=\"1576012002\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AQST\" target=\"_blank\">AQST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525287-aquestive-readies-equity-offering-shares-down-7-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aquestive readies equity offering; shares down 7% after hours</a></h4><ul><li>Aquestive Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AQST' title='Aquestive Therapeutics, Inc.'>AQST</a>) is down <font color=\"red\">7%</font> after hours in response to its <a href=\"https://seekingalpha.com/pr/17724342-aquestive-therapeutics-announces-proposed-public-offering-of-common-stock\" target=\"_blank\">$35M public stock offerin</a>g. Price, volume and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525287\" data-linked=\"Aquestive readies equity offering; shares down 7% after hours\" data-tweet=\"$AQST - Aquestive readies equity offering; shares down 7% after hours https://seekingalpha.com/news/3525287-aquestive-readies-equity-offering-shares-down-7-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3525287-aquestive-readies-equity-offering-shares-down-7-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525283\" data-ts=\"1576011856\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ASPU\" target=\"_blank\">ASPU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525283-aspen-eps-beats-0_04-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aspen EPS beats by $0.04, beats on revenue</a></h4><ul><li>Aspen (NASDAQ:<a href='https://seekingalpha.com/symbol/ASPU' title='Aspen Group, Inc.'>ASPU</a>): Q2 GAAP EPS of -$0.03 <font color=\"green\">beats by $0.04</font>.</li><li>Revenue of $12.09M (+49.3% Y/Y) <font color=\"green\">beats by $0.49M</font>.</li><li>Shares <font color=\"green\">+5.07%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17724339-aspen-group-reports-record-revenue-of-12_1-million-in-second-quarter-fiscal-year-2020\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3525283\" data-linked=\"Aspen EPS beats by $0.04, beats on revenue\" data-tweet=\"$ASPU - Aspen EPS beats by $0.04, beats on revenue https://seekingalpha.com/news/3525283-aspen-eps-beats-0_04-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3525283-aspen-eps-beats-0_04-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525276\" data-ts=\"1576011657\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525276-microsofts-teams-joins-slack-on-linux\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Microsoft&#39;s Teams joins Slack on Linux</a></h4><ul><li>Microsoft's (NASDAQ:<a href='https://seekingalpha.com/symbol/MSFT' title='Microsoft Corporation'>MSFT</a>) Teams <a href=\"https://www.zdnet.com/article/microsoft-teams-for-linux-now-available-in-public-preview/#ftag=RSSbaffb68\" target=\"_blank\">comes to Linux</a> in public preview today with all of the core capabilities available to users.</li><li>Microsoft says Teams is the \"Office app that is coming to Linux desktops.\" The tech giant didn't specify which Office apps will follow.</li><li>Teams rival Slack (NYSE:<a href='https://seekingalpha.com/symbol/WORK' title='Slack Technologies, Inc.'>WORK</a>) already had a Linux client.</li><li>Slack shares closed today <font color=\"red\">down 3.4%</font> to $22.21.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525276\" data-linked=\"Microsoft&#39;s Teams joins Slack on Linux\" data-tweet=\"$MSFT $WORK - Microsoft&#39;s Teams joins Slack on Linux https://seekingalpha.com/news/3525276-microsofts-teams-joins-slack-on-linux?source=tweet\" data-url=\"https://seekingalpha.com/news/3525276-microsofts-teams-joins-slack-on-linux\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525274\" data-ts=\"1576011500\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ENLC\" target=\"_blank\">ENLC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525274-enlink-midstream-rallies-on-back-of-devon-energys-stack-partnership\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EnLink Midstream rallies on back of Devon Energy&#39;s STACK partnership</a></h4><ul><li>EnLink Midstream (<a href='https://seekingalpha.com/symbol/ENLC' title='EnLink Midstream, LLC'>ENLC</a> <font color=\"green\">+15.2%</font>) surges for the second straight session on heavy volume and has jumped ~25% so far this week.</li><li>ENLC <a href=\"https://seekingalpha.com/pr/17723110-enlink-midstream-schedules-february-26-conference-call-to-discuss-fourth-quarter-and-full\" target=\"_blank\">said this morning</a> it planned a webcast and conference call in mid-January to discuss its 2020 financial guidance and strategy, to include the partnership <a href=\"https://seekingalpha.com/news/3525188-devon-energy-dow-to-jointly-develop-oklahoma-shale-acreage\" target=\"_blank\">announced today</a> between Devon Energy - a former affiliate and primary customer of the company - and Dow Inc. to further  develop acreage in Oklahoma's STACK play.</li><li>Investors may see the DVN news as hope for the start of a rebound in oil and gas activity in Oklahoma, where last month the company said it had cut the number of rigs it operated in the Anadarko shale to zero.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525274\" data-linked=\"EnLink Midstream rallies on back of Devon Energy&#39;s STACK partnership\" data-tweet=\"$ENLC - EnLink Midstream rallies on back of Devon Energy&#39;s STACK partnership https://seekingalpha.com/news/3525274-enlink-midstream-rallies-on-back-of-devon-energys-stack-partnership?source=tweet\" data-url=\"https://seekingalpha.com/news/3525274-enlink-midstream-rallies-on-back-of-devon-energys-stack-partnership\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525272\" data-ts=\"1576011107\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525272-uber-lyft-can-raise-prices-to-profit-barclays\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Uber, Lyft can raise prices to profit - Barclays</a></h4><ul><li>Barclays analysts <a href=\"https://www.bloomberg.com/news/articles/2019-12-10/apple-s-new-mac-can-cost-52-000-that-s-without-the-400-wheels\" target=\"_blank\">say </a>Uber (<a href='https://seekingalpha.com/symbol/UBER' title='Uber Technologies, Inc.'>UBER</a> <font color='green'>+0.9%</font>) and Lyft (<a href='https://seekingalpha.com/symbol/LYFT' title='Lyft, Inc.'>LYFT</a> <font color='red'>-0.5%</font>) are well-positioned to achieve profitability.</li><li>The group of analysts cites a Barclays analysis of about 2.4B taxi and ride-hailing trips in NYC and how raising prices affected the number of rides. The introduction of a congestion tax in the city provided a natural experiment for the price elasticity of demand.</li><li>Barclays says the companies can raise prices to achieve a profit with only a small impact on volumes, which disproves \"a key piece of the bear case.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3525272\" data-linked=\"Uber, Lyft can raise prices to profit - Barclays\" data-tweet=\"$UBER $LYFT - Uber, Lyft can raise prices to profit - Barclays https://seekingalpha.com/news/3525272-uber-lyft-can-raise-prices-to-profit-barclays?source=tweet\" data-url=\"https://seekingalpha.com/news/3525272-uber-lyft-can-raise-prices-to-profit-barclays\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525270\" data-ts=\"1576010363\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FQVLF\" target=\"_blank\">FQVLF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525270-first-quantum-pours-cold-water-on-takeover-talk\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">First Quantum pours cold water on takeover talk</a></h4><ul><li>First Quantum Minerals (<a href='https://seekingalpha.com/symbol/FQVLF' title='First Quantum Minerals Ltd.'>OTCPK:FQVLF</a> <font color='red'>-1.8%</font>) says it has <a href=\"https://www.bnnbloomberg.ca/first-quantum-quashes-rio-rumor-and-says-jiangxi-no-threat-1.1360582\" target=\"_blank\">not received any takeover  approaches</a>, including from Rio Tinto (<a href='https://seekingalpha.com/symbol/RIO' title='Rio Tinto Group'>RIO</a> <font color='green'>+0.3%</font>), since it last quashed  rumors <a href=\"https://seekingalpha.com/news/3501087-first-quantum-minerals-swears-off-takeover-talks\" target=\"_blank\">in September</a>.</li><li>While the company was surprised by <a href=\"https://seekingalpha.com/news/3524992-first-quantum-jumps-after-jiangxi-copper-buys-part-of-top-shareholder\" target=\"_blank\">this week's share purchase</a> by  Jiangxi Copper, there's no chance that will lead to a takeover bid  either, First Quantum President Clive Newall tells Bloomberg.</li><li>Jiangxi initially approached First Quantum about acquiring a  minority stake in its Zambian assets, Newall says, adding that as part of those  talks, the company required Jiangxi to sign a non-disclosure agreement  that restricts it from buying more than 20% of First Quantum shares.</li><li>The restriction will not expire for \"at least a couple of  years\" and was negotiated to eliminate any possibility of a takeover  play by the Chinese miner, he says.</li><li>As for the <a href=\"https://seekingalpha.com/news/3522513-rio-tinto-first-quantum-in-talks-over-peru-copper-mine-ft\" target=\"_blank\">Rio rumors</a>, Newall says the talk is just \"scuttlebutt\" and the company has not received takeover interest from anyone since September, when it previously denied takeover  interest.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525270\" data-linked=\"First Quantum pours cold water on takeover talk\" data-tweet=\"$FQVLF $RIO - First Quantum pours cold water on takeover talk https://seekingalpha.com/news/3525270-first-quantum-pours-cold-water-on-takeover-talk?source=tweet\" data-url=\"https://seekingalpha.com/news/3525270-first-quantum-pours-cold-water-on-takeover-talk\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525263\" data-ts=\"1576007841\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525263-tcco-leads-technology-gainers-bhat-and-agmh-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TCCO leads technology gainers; BHAT and AGMH among losers</a></h4><ul><li><b>Gainers:</b> Technical Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/TCCO' title='Technical Communications Corporation'>TCCO</a>) <font color=\"green\">+298%</font>. Evolent Health (NYSE:<a href='https://seekingalpha.com/symbol/EVH' title='Evolent Health, Inc.'>EVH</a>) <font color=\"green\">+13%</font>. Wrap Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/WRTC' title='Wrap Technologies, Inc.'>WRTC</a>) <font color=\"green\">+9%</font>. Gravity (NASDAQ:<a href='https://seekingalpha.com/symbol/GRVY' title='Gravity Co., Ltd.'>GRVY</a>) <font color=\"green\">+9%</font>. GTT Communications (NYSE:<a href='https://seekingalpha.com/symbol/GTT' title='GTT Communications, Inc.'>GTT</a>) <font color=\"green\">+8%</font>.</li><li><b>Losers:</b> Intelsat (NYSE:<a href='https://seekingalpha.com/symbol/I' title='Intelsat S.A.'>I</a>) <font color=\"red\">-8%</font>. Intellicheck (NYSEMKT:<a href='https://seekingalpha.com/symbol/IDN' title='Intellicheck, Inc.'>IDN</a>) <font color=\"red\">-8%</font>. Fujian Blue Hat Interactive Entertainment Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/BHAT' title='Fujian Blue Hat Interactive Entertainment Technology Ltd.'>BHAT</a>) <font color=\"red\">-6%</font>. Marin Software (NASDAQ:<a href='https://seekingalpha.com/symbol/MRIN' title='Marin Software Incorporated'>MRIN</a>) <font color=\"red\">-6%</font>. AGM Group Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/AGMH' title='AGM Group Holdings Inc.'>AGMH</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525263\" data-linked=\"TCCO leads technology gainers; BHAT and AGMH among losers\" data-tweet=\"$TCCO $EVH $WRTC - TCCO leads technology gainers; BHAT and AGMH among losers https://seekingalpha.com/news/3525263-tcco-leads-technology-gainers-bhat-and-agmh-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3525263-tcco-leads-technology-gainers-bhat-and-agmh-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:57 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525259\" data-ts=\"1576006140\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MAXR\" target=\"_blank\">MAXR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525259-maxar-closes-real-estate-sale-leaseback-for-291m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Maxar closes real estate sale-leaseback for $291M</a></h4><ul>   <li>Maxar Technologies (<a href=\"http://seekingalpha.com/symbol/MAXR\" target=\"_blank\">MAXR</a> <font color=\"green\">+2%</font>) has <a href=\"https://seekingalpha.com/pr/17724228-maxar-technologies-announces-closing-of-palo-alto-real-estate-transactions\" target=\"_blank\">closed</a> real estate sale-leaseback transactions in Palo Alto, Calif., for gross proceeds of $291M.</li>    <li>It will use funds from that sale and its senior debt offering to repay all borrowings outstanding on its revolving credit as of Sept. 30, and term loans A-1 and A-2 under a syndicated credit facility.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3525259\" data-linked=\"Maxar closes real estate sale-leaseback for $291M\" data-tweet=\"$MAXR - Maxar closes real estate sale-leaseback for $291M https://seekingalpha.com/news/3525259-maxar-closes-real-estate-sale-leaseback-for-291m?source=tweet\" data-url=\"https://seekingalpha.com/news/3525259-maxar-closes-real-estate-sale-leaseback-for-291m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525257\" data-ts=\"1576005616\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AZO\" target=\"_blank\">AZO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525257-buyback-magic-autozone\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Buyback magic at AutoZone</a></h4><ul> <li>Whitney Tilson has something to say about the stellar share price performance of AutoZone (<a href='https://seekingalpha.com/symbol/AZO' title='AutoZone, Inc.'>AZO</a> <font color=\"green\">+7%</font>) over the last ten years, which ranks it near the top of the retail sector.</li> <li>\"I hope you're sitting down, because AutoZone has bought back an astounding 84% of its outstanding shares since 1998,\" writes Tilson.</li> <li>\"As a result, while earnings have grown sixfold, earnings per share grew by 34 times since 2001,\" he calculates.</li> <li>Tilson reminds that the buyback magic at AutoZone can be traced back to Eddie Lampert when he was an activist investor.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3525257\" data-linked=\"Buyback magic at AutoZone\" data-tweet=\"$AZO - Buyback magic at AutoZone https://seekingalpha.com/news/3525257-buyback-magic-autozone?source=tweet\" data-url=\"https://seekingalpha.com/news/3525257-buyback-magic-autozone\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525255\" data-ts=\"1576005409\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EVH\" target=\"_blank\">EVH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525255-evolent-health-up-11-on-renewed-hopes-kentucky-medicaid-contract\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Evolent Health up 11% on renewed hopes with Kentucky Medicaid contract</a></h4><ul><li>Evolent Health (<a href='https://seekingalpha.com/symbol/EVH' title='Evolent Health, Inc.'>EVH</a> <font color=\"green\">+11.3%</font>) jumps on almost double normal volume in response to the <a href=\"https://www.wdrb.com/in-depth/kentucky-legislators-block-gov-bevin-s-medicaid-deal-reviving-hope/article_fa779a4e-1abc-11ea-8901-a3941cb5682f.html\" target=\"_blank\">news </a>that the Kentucky legislature has voted against outgoing Governor Matt Bevin's decision to award the state's Medicaid contract to five insurers, excluding nonprofit Passport Health Plan [and Anthem (<a href='https://seekingalpha.com/symbol/ANTM' title='Anthem, Inc.'>ANTM</a>)] in favor of UnitedHealthcare (<a href='https://seekingalpha.com/symbol/UNH' title='UnitedHealth Group Incorporated'>UNH</a> <font color=\"green\">+0.4%</font>) and Molina (<a href='https://seekingalpha.com/symbol/MOH' title='Molina Healthcare, Inc.'>MOH</a> <font color=\"red\">-0.4%</font>).</li><li>The about-face gives new life to Passport, which generates almost all of its $2B annual revenue from the state Medicaid contract, an acquisition target of Evolent's.</li><li>Evolent shares plunged <font color=\"red\">34%</font> in late November in response to <a href=\"https://seekingalpha.com/news/3522421-evolent-health-plunges-after-kentucky-medicaid-contract-news\" target=\"_blank\">Gov. Bevin's action</a>.</li><li><strong>Update</strong>: On December 11, the Courier Journal <a href=\"https://www.courier-journal.com/story/news/politics/elections/kentucky/2019/12/11/kentucky-medicaid-bevin-official-snubs-passport-final-hours/4397395002/\" target=\"_blank\">reported </a>that Gov. Bevin's administration overrode the rejection and all five contracts will remain in effect. The administration of new Governor Andy Beshear has pledged to review the contract decisions. Evolent is down <font color=\"red\">11%</font> on below-average volume mid-session.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525255\" data-linked=\"Evolent Health up 11% on renewed hopes with Kentucky Medicaid contract\" data-tweet=\"$EVH $ANTM $UNH - Evolent Health up 11% on renewed hopes with Kentucky Medicaid contract https://seekingalpha.com/news/3525255-evolent-health-up-11-on-renewed-hopes-kentucky-medicaid-contract?source=tweet\" data-url=\"https://seekingalpha.com/news/3525255-evolent-health-up-11-on-renewed-hopes-kentucky-medicaid-contract\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525254\" data-ts=\"1576004738\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ETM\" target=\"_blank\">ETM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525254-entercom-launches-100m-add-on-offering-of-6_500-senior-secured-second-lien-notes-due-2027\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Entercom launches $100M add-on offering of 6.500% senior secured second-lien notes due 2027</a></h4><ul> <li>Entercom Media Corp., a wholly owned subsidiary of Entercom Communications (<a href='https://seekingalpha.com/symbol/ETM' title='Entercom Communications Corp.'>ETM</a> <font color='red'>-1.9%</font>) to <a href=\"https://seekingalpha.com/pr/17723538-entercom-announces-launch-of-100-million-add-on-offering-of-6_500-senior-secured-second-lien\" target=\"_blank\">offer</a> $100M of the Issuer\u2019s 6.500% senior secured second-lien notes due 2027.</li><li>Net proceeds of this offering will be used to partially repay existing indebtedness under senior secured term loan facility.</li> <li>The notes are being offered as additional notes under an existing indenture, dated April 30, 2019, pursuant to which the Issuer previously issued $325M in aggregate principal amount of its 6.500% senior secured second-lien notes due 2027.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525254\" data-linked=\"Entercom launches $100M add-on offering of 6.500% senior secured second-lien notes due 2027\" data-tweet=\"$ETM - Entercom launches $100M add-on offering of 6.500% senior secured second-lien notes due 2027 https://seekingalpha.com/news/3525254-entercom-launches-100m-add-on-offering-of-6_500-senior-secured-second-lien-notes-due-2027?source=tweet\" data-url=\"https://seekingalpha.com/news/3525254-entercom-launches-100m-add-on-offering-of-6_500-senior-secured-second-lien-notes-due-2027\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:05 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525252\" data-ts=\"1576004531\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525252-enlink-midstream-leads-energy-materials-gainers-noble-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EnLink Midstream leads energy/materials gainers; Noble among losers</a></h4><ul><li><b>Gainers: </b>EnLink Midstream (NYSE:<a href='https://seekingalpha.com/symbol/ENLC' title='EnLink Midstream, LLC'>ENLC</a>) <font color=\"green\">+15%</font>. Summit Midstream Partners (NYSE:<a href='https://seekingalpha.com/symbol/SMLP' title='Summit Midstream Partners, LP'>SMLP</a>) <font color=\"green\">+11%</font>. KLX Energy Services (NASDAQ:<a href='https://seekingalpha.com/symbol/KLXE' title='KLX Energy Services Holdings, Inc.'>KLXE</a>) <font color=\"green\">+10%</font>. PEDEVCO (NYSEMKT:<a href='https://seekingalpha.com/symbol/PED' title='PEDEVCO Corp.'>PED</a>) <font color=\"green\">+10%</font>. Calumet Specialty Products (NASDAQ:<a href='https://seekingalpha.com/symbol/CLMT' title='Calumet Specialty Products Partners, L.P.'>CLMT</a>) <font color=\"green\">+7%</font>.</li><li><b>Losers: </b>TuanChe (NASDAQ:<a href='https://seekingalpha.com/symbol/TC' title='TuanChe Limited'>TC</a>) <font color=\"red\">-12%</font>. Noble (NYSE:<a href='https://seekingalpha.com/symbol/NE' title='Noble Corporation plc'>NE</a>) <font color=\"red\">-8%</font>. Marrone Bio Innovations (NASDAQ:<a href='https://seekingalpha.com/symbol/MBII' title='Marrone Bio Innovations, Inc.'>MBII</a>) <font color=\"red\">-8%</font>. Tantech Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/TANH' title='Tantech Holdings Ltd'>TANH</a>) <font color=\"red\">-7%</font>. SAExploration (NASDAQ:<a href='https://seekingalpha.com/symbol/SAEX' title='SAExploration Holdings, Inc.'>SAEX</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525252\" data-linked=\"EnLink Midstream leads energy/materials gainers; Noble among losers\" data-tweet=\"$ENLC $SMLP $KLXE - EnLink Midstream leads energy/materials gainers; Noble among losers https://seekingalpha.com/news/3525252-enlink-midstream-leads-energy-materials-gainers-noble-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3525252-enlink-midstream-leads-energy-materials-gainers-noble-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525390\" data-ts=\"1576004062\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IP\" target=\"_blank\">IP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525390-international-paper-slashed-to-sell-goldman-on-containerboard-price-risk\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">International Paper slashed to Sell at Goldman on containerboard price risk</a></h4><ul><li>International Paper (<a href='https://seekingalpha.com/symbol/IP' title='International Paper Company'>IP</a> <font color='red'>-2.5%</font>) is <a href=\"https://thefly.com/thestreet/realmoney/index.php/IP;PKGid3004391/IP;PKG-International-Paper-downgraded-to-Sell-from-Neutral-at-Goldman-Sachs\" target=\"_blank\">downgraded to Sell</a> from Neutral with a $40 price target at Goldman Sachs, which cites concerns over  containerboard pricing in 2020 as well as earnings risks at other parts  of the company's business.</li><li>IP shares have outperformed the market over the past three months despite downward revisions to 2020  consensus estimates, Goldman's Brian Maguire says, lifting the stock's valuation in line with its historical  average, despite the heightened risk of containerboard price cuts.</li><li>Maguire expects an 8.4% increase in North American  capacity to enter the market starting in 2020, as well as weak demand from a  slowing industrial economy.</li><li>Goldman <a href=\"https://seekingalpha.com/news/3525056-packaging-corp-of-americaminus-1-after-goldman-cut\" target=\"_blank\">also downgraded</a> Packaging Corp. of America to Sell.</li><li>IP's average <a href=\"https://seekingalpha.com/symbol/IP/ratings/sell-side-ratings\" target=\"_blank\">Sell Side Rating</a>, <a href=\"https://seekingalpha.com/symbol/IP/ratings/author-ratings#filter=all\" target=\"_blank\">Seeking Alpha Authors' Rating</a> and <a href=\"https://seekingalpha.com/symbol/IP/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> are all Neutral.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525390\" data-linked=\"International Paper slashed to Sell at Goldman on containerboard price risk\" data-tweet=\"$IP - International Paper slashed to Sell at Goldman on containerboard price risk https://seekingalpha.com/news/3525390-international-paper-slashed-to-sell-goldman-on-containerboard-price-risk?source=tweet\" data-url=\"https://seekingalpha.com/news/3525390-international-paper-slashed-to-sell-goldman-on-containerboard-price-risk\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:54 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525249\" data-ts=\"1576003960\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LLNW\" target=\"_blank\">LLNW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525249-limelight-networks-issues-initial-guidance-for-fy2020\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Limelight Networks issues initial guidance for FY2020</a></h4><ul> <li>Limelight Networks (<a href='https://seekingalpha.com/symbol/LLNW' title='Limelight Networks, Inc.'>LLNW</a> <font color=\"red\">-4.2%</font>) <a href=\"https://seekingalpha.com/pr/17723610-limelight-networks-guidance-for-2020\" target=\"_blank\">expects</a> FY2020 revenue to be between $220M and $235M; GAAP EPS between $(0.10) and $0.00; Non-GAAP EPS between $0.00 and $0.10; Adjusted EBITDA between $25M and $35M; Capital Expenditures between $25M and $30M.</li>  <li>\"Our business has meaningfully improved through 2019. We are confident that our 2019 exit run rates will be strong, which gives us conviction in our ability to deliver against our 2020 guidance. We believe the four quarters in 2020 will show sequential revenue growth and related margin improvements. Our plan is to continue to invest in the business to capture growth opportunities. At the same time, the business model leverage should be evident in the anticipated improvement in operating margins and free cash flow in light of the expected decline in capital expenditures,\" said Bob Lento, Limelight's Chief Executive Officer.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3525249\" data-linked=\"Limelight Networks issues initial guidance for FY2020\" data-tweet=\"$LLNW - Limelight Networks issues initial guidance for FY2020 https://seekingalpha.com/news/3525249-limelight-networks-issues-initial-guidance-for-fy2020?source=tweet\" data-url=\"https://seekingalpha.com/news/3525249-limelight-networks-issues-initial-guidance-for-fy2020\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:52 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525247\" data-ts=\"1576003830\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525247-bofa-bullish-on-under-owned-semi-stocks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BofA bullish on under-owned semi stocks</a></h4><ul><li>Bank of America says several major semiconductor companies are under-owned by funds, creating an \"attractive opportunity.\"</li><li>Nvidia (<a href='https://seekingalpha.com/symbol/NVDA' title='NVIDIA Corporation'>NVDA</a> <font color='green'>+1.2%</font>) is \"owned by 28% of fund managers with 0.90x weighting (vs. semis at 1.19x),\" says BofA.</li><li>Analyst Vivek Arya says NVDA is \"well positioned to address some of the largest and fastest-growing parts of technology,\" including gaming, self-driving cars, and AI.</li><li>BofA also sees Synopsys (<a href='https://seekingalpha.com/symbol/SNPS' title='Synopsys, Inc.'>SNPS</a>) as \"particularly attractive\" since the company is \"under-owned and underweight\" by funds.</li><li>KLA (<a href='https://seekingalpha.com/symbol/KLAC' title='KLA Corporation'>KLAC</a> <font color='green'>+1.6%</font>) also makes the list with only 11.6% fund ownership.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525247\" data-linked=\"BofA bullish on under-owned semi stocks\" data-tweet=\"$NVDA $SNPS $KLAC - BofA bullish on under-owned semi stocks https://seekingalpha.com/news/3525247-bofa-bullish-on-under-owned-semi-stocks?source=tweet\" data-url=\"https://seekingalpha.com/news/3525247-bofa-bullish-on-under-owned-semi-stocks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525246\" data-ts=\"1576003679\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525246-viacomcbs-back-in-talks-over-miramax-stake-variety\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ViacomCBS back in talks over Miramax stake - Variety</a></h4><ul>   <li>ViacomCBS (<a href='https://seekingalpha.com/symbol/VIAC' title='ViacomCBS Inc.'>VIAC</a> <font color=\"red\">-1.8%</font>, <a href='https://seekingalpha.com/symbol/VIACA' title='ViacomCBS Inc.'>VIACA</a> <font color=\"red\">-0.3%</font>) and its Paramount Pictures are <a href=\"https://variety.com/2019/film/news/viacomcbs-paramount-resume-talks-to-buy-stake-in-miramax-exclusive-1203431208/\" target=\"_blank\">back in talks</a> to take a stake in Miramax, Variety reports.</li>    <li>There's no deal yet, and the two broke off discussions last month amid frustration over terms.</li>    <li>But new talks, for a deal in the low nine figures, would see ViacomCBS/Paramount become an equity investor and make movies/shows based on Miramax intellectual property, according to the report.</li>    <li>Miramax is owned by beIN, which acquired it in 2016.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3525246\" data-linked=\"ViacomCBS back in talks over Miramax stake - Variety\" data-tweet=\"$VIAC $VIACA - ViacomCBS back in talks over Miramax stake - Variety https://seekingalpha.com/news/3525246-viacomcbs-back-in-talks-over-miramax-stake-variety?source=tweet\" data-url=\"https://seekingalpha.com/news/3525246-viacomcbs-back-in-talks-over-miramax-stake-variety\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525245\" data-ts=\"1576003148\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MC\" target=\"_blank\">MC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525245-moelis-mulls-boosting-bankers-pay-sharesminus-5_0\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Moelis mulls boosting its bankers&#39; pay; shares -5.0%</a></h4><ul><li>Moelis &amp; Co. (NYSE:<a href='https://seekingalpha.com/symbol/MC' title='Moelis & Company'>MC</a>)<font color=\"red\"> falls 5.0%</font> after its founder, Chairman, and CEO <a href=\"https://event.webcasts.com/viewer/event.jsp?ei=1273756&amp;tp_key=d155a9d988\" target=\"_blank\">Ken Moelis speaks</a> at Goldman Sachs's financial conference.</li><li>Speaking about the company's pretax margin staying within 25%-27% since it went public in 2014, Moelis said, \"That's a fair band over the long haul.\"</li><li>The company is thinking about \"taking something out of the margin in terms of the comp ratio,\" bringing that to the \"low-60s to mid-60s in order to make sure that this team is on the field\" for what happens over the next five years.</li><li>Still, he said, \"the decision isn't made yet.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3525245\" data-linked=\"Moelis mulls boosting its bankers&#39; pay; shares -5.0%\" data-tweet=\"$MC - Moelis mulls boosting its bankers&#39; pay; shares -5.0% https://seekingalpha.com/news/3525245-moelis-mulls-boosting-bankers-pay-sharesminus-5_0?source=tweet\" data-url=\"https://seekingalpha.com/news/3525245-moelis-mulls-boosting-bankers-pay-sharesminus-5_0\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525243\" data-ts=\"1576002610\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UPWK\" target=\"_blank\">UPWK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525243-rbc-less-constructive-on-upworks-ceo-change\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RBC less constructive on Upwork&#39;s CEO change</a></h4><ul><li>Yesterday, Upwork (<a href='https://seekingalpha.com/symbol/UPWK' title='Upwork Inc.'>UPWK</a> <font color=\"red\">-5.5%</font>) <a href=\"https://seekingalpha.com/pr/17722730-upwork-announces-leadership-transition\" target=\"_blank\">announced</a> that President and CEO Stephane Kasriel would step down at the end of the year.</li><li>The board appointed current Chief Marketing &amp; Product Officer Hayden Brown to step into Kasriel's roles, effective January 1.</li><li>Kasriel will remain on as an advisor and in a board seat until the 2020 annual meeting.</li><li>RBC analyst Mark Mahaney says, \"Management changes like this make us less constructive on Upwork.\"</li><li>Mahaney praises UPWK's long-term story and expects the near-term investments to continue to grow.</li><li>RBC maintains an Outperform rating and $20 price target on Upwork. The company has a Bullish average <a href=\"https://seekingalpha.com/symbol/UPWK/ratings/sell-side-ratings\" target=\"_blank\">Sell Side rating</a>.</li><li>UPWK shares are <font color=\"red\">down 5.3%</font> to $10.56.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525243\" data-linked=\"RBC less constructive on Upwork&#39;s CEO change\" data-tweet=\"$UPWK - RBC less constructive on Upwork&#39;s CEO change https://seekingalpha.com/news/3525243-rbc-less-constructive-on-upworks-ceo-change?source=tweet\" data-url=\"https://seekingalpha.com/news/3525243-rbc-less-constructive-on-upworks-ceo-change\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:30 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525239\" data-ts=\"1576001476\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525239-strs-leads-financial-gainers-wei-and-rhp-only-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">STRS leads financial gainers; WEI and RHP the only losers</a></h4><ul><li><b>Gainers:</b> Stratus Properties (NASDAQ:<a href='https://seekingalpha.com/symbol/STRS' title='Stratus Properties Inc.'>STRS</a>) <font color=\"green\">+13%</font>. Bat Group (NASDAQ:<a href='https://seekingalpha.com/symbol/GLG' title='Bat Group, Inc.'>GLG</a>) <font color=\"green\">+7%</font>. Vista Oil &amp; Gas (NYSE:<a href='https://seekingalpha.com/symbol/VIST' title='Vista Oil & Gas, S.A.B. de C.V.'>VIST</a>) <font color=\"green\">+7%</font>. BBX Capital (NYSE:<a href='https://seekingalpha.com/symbol/BBX' title='BBX Capital Corporation'>BBX</a>) <font color=\"green\">+5%</font>. FedNat Holding (NASDAQ:<a href='https://seekingalpha.com/symbol/FNHC' title='FedNat Holding Company'>FNHC</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers:</b> Weidai (NYSE:<a href='https://seekingalpha.com/symbol/WEI' title='Weidai Ltd.'>WEI</a>) <font color=\"red\">-16%</font>. Ryman Hospitality Properties (NYSE:<a href='https://seekingalpha.com/symbol/RHP' title='Ryman Hospitality Properties, Inc.'>RHP</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525239\" data-linked=\"STRS leads financial gainers; WEI and RHP the only losers\" data-tweet=\"$STRS $GLG $VIST - STRS leads financial gainers; WEI and RHP the only losers https://seekingalpha.com/news/3525239-strs-leads-financial-gainers-wei-and-rhp-only-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3525239-strs-leads-financial-gainers-wei-and-rhp-only-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:11 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525237\" data-ts=\"1576000925\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525237-ideal-power-only-industrial-gainer-capstone-turbine-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ideal Power only industrial gainer; Capstone Turbine among losers</a></h4><ul><li><b>Gainers: </b>Ideal Power (NASDAQ:<a href='https://seekingalpha.com/symbol/IPWR' title='Ideal Power Inc.'>IPWR</a>) <font color=\"green\">+9%</font>.</li><li><b>Losers: </b>Construction Partners (NASDAQ:<a href='https://seekingalpha.com/symbol/ROAD' title='Construction Partners, Inc.'>ROAD</a>) <font color=\"red\">-22%</font>. Babcock &amp; Wilcox (NYSE:<a href='https://seekingalpha.com/symbol/BW' title='Babcock & Wilcox Enterprises, Inc.'>BW</a>) <font color=\"red\">-5%</font>. Hebron Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/HEBT' title='Hebron Technology Co., Ltd.'>HEBT</a>) <font color=\"red\">-5%</font>. Capstone Turbine (NASDAQ:<a href='https://seekingalpha.com/symbol/CPST' title='Capstone Turbine Corporation'>CPST</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525237\" data-linked=\"Ideal Power only industrial gainer; Capstone Turbine among losers\" data-tweet=\"$IPWR $ROAD $BW - Ideal Power only industrial gainer; Capstone Turbine among losers https://seekingalpha.com/news/3525237-ideal-power-only-industrial-gainer-capstone-turbine-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3525237-ideal-power-only-industrial-gainer-capstone-turbine-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525233\" data-ts=\"1576000070\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEN\" target=\"_blank\">TEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525233-tenneco-catches-bid-from-apollo-for-unit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tenneco catches bid from Apollo for unit</a></h4><ul> <li>Tenneco (<a href='https://seekingalpha.com/symbol/TEN' title='Tenneco Inc.'>TEN</a> <font color='green'>+8.2%</font>) rallies after <em>The Wall Street Journal</em> reports Apollo Global Management made a <a href=\"https://www.wsj.com/articles/breaking-news-apollo-makes-bid-for-tennecos-powertrain-unit-sources-11575998488\" target=\"_blank\">bid</a> for the company's powertrain unit.</li> <li>Sources indicate the offer came within the last few days,</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3525233\" data-linked=\"Tenneco catches bid from Apollo for unit\" data-tweet=\"$TEN - Tenneco catches bid from Apollo for unit https://seekingalpha.com/news/3525233-tenneco-catches-bid-from-apollo-for-unit?source=tweet\" data-url=\"https://seekingalpha.com/news/3525233-tenneco-catches-bid-from-apollo-for-unit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525230\" data-ts=\"1575999838\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PPLT\" target=\"_blank\">PPLT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525230-palladium-roars-to-record-1900-oz-on-south-africa-power-cuts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Palladium roars to record $1,900/oz. on South Africa power cuts</a></h4><ul><li>Palladium spot prices (NYSEARCA:<a href='https://seekingalpha.com/symbol/PPLT' title='Aberdeen Standard Physical Platinum Shares ETF'>PPLT</a>) <a href=\"https://www.reuters.com/article/global-precious/precious-palladium-breaks-1900-ceiling-after-south-africa-outages-idUSL4N28K3IW\" target=\"_blank\">push past $1,900/oz. for the first time ever</a> as <a href=\"https://seekingalpha.com/news/3525113-severe-south-african-power-shortages-cut-mining-production\" target=\"_blank\">South Africa's power crisis</a> halts mining production in the country, exacerbating supply concerns and extending the metal's record run.</li><li>Spot palladium recently was <font color=\"green\">+1%</font> at $1,901.27/oz., after hitting an all-time high $1,903/oz.</li><li>\"South Africa produces 40% of world's palladium and the ESKOM outages are hitting some mines, giving palladium just that extra nudge above $1,900,\" says Tai Wong, head of base and precious metals derivatives trading at BMO, but after 13 straight positive sessions, \"it wouldn't be surprising to see some consolidation, though the overall trend continues to look positive.\"</li><li>Scarcity concerns over palladium already have helped lift the metal by ~50% in 2019, due to its large demand in the auto sector.</li><li>Other metals also gained on the South African outages, with platinum <font color=\"green\">+3.1%</font> at $922.40/oz., the highest since Nov. 21, and silver <font color=\"green\">+0.4%</font> to $16.66/oz.; spot gold only <font color=\"green\">+0.1%</font> at $1,463.66/oz.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/PPLT' title='Aberdeen Standard Physical Platinum Shares ETF'>PPLT</a>, <a href='https://seekingalpha.com/symbol/PLTM' title='GraniteShares Platinum Trust'>PLTM</a>, <a href='https://seekingalpha.com/symbol/PTM' title='UBS ETRACS CMCI Long Platinum Total Return ETN'>PTM</a>, <a href='https://seekingalpha.com/symbol/PGM' title='iPath Series B Bloomberg Platinum Subindex Total Return ETN'>PGM</a>, <a href='https://seekingalpha.com/symbol/SLV' title='iShares Silver Trust ETF'>SLV</a>, <a href='https://seekingalpha.com/symbol/USLV' title='VelocityShares 3x Long Silver ETN'>USLV</a>, <a href='https://seekingalpha.com/symbol/AGQ' title='ProShares Ultra Silver ETF'>AGQ</a>, <a href='https://seekingalpha.com/symbol/PSLV' title='Sprott Physical Silver Trust'>PSLV</a>, <a href='https://seekingalpha.com/symbol/SIVR' title='Aberd Std Silvr Shs'>SIVR</a>, <a href='https://seekingalpha.com/symbol/PALL' title='Aberdeen Standard Physical Palladium Shares ETF'>PALL</a>, <a href='https://seekingalpha.com/symbol/ZSL' title='ProShares Trust II - ProShares UltraShort Silver'>ZSL</a>, <a href='https://seekingalpha.com/symbol/DSLV' title='VelocityShares 3x Inverse Silver ETN'>DSLV</a>, <a href='https://seekingalpha.com/symbol/DBS' title='Invesco DB Silver ETF'>DBS</a>, <a href='https://seekingalpha.com/symbol/USV' title='ETRACS CMCI Silver Total Return ETN'>USV</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3525230\" data-linked=\"Palladium roars to record $1,900/oz. on South Africa power cuts\" data-tweet=\"$PPLT $PLTM $PTM - Palladium roars to record $1,900/oz. on South Africa power cuts https://seekingalpha.com/news/3525230-palladium-roars-to-record-1900-oz-on-south-africa-power-cuts?source=tweet\" data-url=\"https://seekingalpha.com/news/3525230-palladium-roars-to-record-1900-oz-on-south-africa-power-cuts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525229\" data-ts=\"1575999627\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525229-auph-dbi-fran-and-nltx-among-midday-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AUPH, DBI, FRAN and NLTX among midday movers</a></h4><ul><li><strong>Gainers: </strong>Technical Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/TCCO' title='Technical Communications Corporation'>TCCO</a>) <font color=\"green\">+323%</font>.</li><li>Venus Concept (NASDAQ:<a href='https://seekingalpha.com/symbol/VERO' title='Venus Concept Inc.'>VERO</a>) <font color=\"green\">+57%</font>.</li><li>Iterum Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ITRM' title='Iterum Therapeutics plc'>ITRM</a>) <font color=\"green\">+35%</font>.</li><li>Neoleukin Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/NLTX' title='Neoleukin Therapeutics, Inc.'>NLTX</a>) <font color=\"green\">+30%</font>.</li><li>Eloxx Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ELOX' title='Eloxx Pharmaceuticals, Inc.'>ELOX</a>) <font color=\"green\">+23%</font>.</li><li>LMP Automotive (NASDAQ:<a href='https://seekingalpha.com/symbol/LMPX' title='LMP Automotive Holdings, Inc.'>LMPX</a>) <font color=\"green\">+22%</font>.</li><li>Xtant Medical (NYSEMKT:<a href='https://seekingalpha.com/symbol/XTNT' title='Xtant Medical Holdings, Inc.'>XTNT</a>) <font color=\"green\">+20%</font>.</li><li>Boxwood Merger (NASDAQ:<a href='https://seekingalpha.com/symbol/BWMC' title='Boxwood Merger Corp.'>BWMC</a>) <font color=\"green\">+17%</font>.</li><li>Principia Biopharma (NASDAQ:<a href='https://seekingalpha.com/symbol/PRNB' title='Principia Biopharma Inc.'>PRNB</a>) <font color=\"green\">+16%</font>.</li><li>Aurinia Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/AUPH' title='Aurinia Pharmaceuticals Inc.'>AUPH</a>) <font color=\"green\">+16%</font>.</li><li><strong>Losers: </strong>Francesca's Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/FRAN' title='Francesca&#39;s Holdings Corporation'>FRAN</a>) <font color=\"red\">-38%</font>.</li><li>Conn's (NASDAQ:<a href='https://seekingalpha.com/symbol/CONN' title='Conn&#39;s, Inc.'>CONN</a>) <font color=\"red\">-31%</font>.</li><li>Construction Partners (NASDAQ:<a href='https://seekingalpha.com/symbol/ROAD' title='Construction Partners, Inc.'>ROAD</a>) <font color=\"red\">-23%</font>.</li><li>Designer Brands (NYSE:<a href='https://seekingalpha.com/symbol/DBI' title='Designer Brands Inc.'>DBI</a>) <font color=\"red\">-17%</font>.</li><li>Achieve Life Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/ACHV' title='Achieve Life Sciences, Inc.'>ACHV</a>) <font color=\"red\">-16%</font>.</li><li>Chimerix (NASDAQ:<a href='https://seekingalpha.com/symbol/CMRX' title='Chimerix, Inc.'>CMRX</a>) <font color=\"red\">-13%</font>.</li><li>Weidai (NYSE:<a href='https://seekingalpha.com/symbol/WEI' title='Weidai Ltd.'>WEI</a>) <font color=\"red\">-12%</font>.</li><li>DermTech (NASDAQ:<a href='https://seekingalpha.com/symbol/DMTK' title='DermTech, Inc.'>DMTK</a>) <font color=\"red\">-11%</font>.</li><li>Kaixin Auto (NASDAQ:<a href='https://seekingalpha.com/symbol/KXIN' title='Kaixin Auto Holdings'>KXIN</a>) <font color=\"red\">-9%</font>.</li><li>Hermitage Offshore Services (NYSE:<a href='https://seekingalpha.com/symbol/PSV' title='Hermitage Offshore Services Ltd.'>PSV</a>) <font color=\"red\">-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525229\" data-linked=\"AUPH, DBI, FRAN and NLTX among midday movers\" data-tweet=\"$TCCO $VERO $ITRM - AUPH, DBI, FRAN and NLTX among midday movers https://seekingalpha.com/news/3525229-auph-dbi-fran-and-nltx-among-midday-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3525229-auph-dbi-fran-and-nltx-among-midday-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525224\" data-ts=\"1575998168\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CF\" target=\"_blank\">CF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525224-cf-cut-to-sell-equivalent-bernstein-on-falling-chinese-coal-prices\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CF cut to Sell equivalent at Bernstein on falling Chinese coal prices</a></h4><ul><li>CF Industries (<a href='https://seekingalpha.com/symbol/CF' title='CF Industries Holdings, Inc.'>CF</a> <font color='red'>-2.7%</font>) falls sharply after Bernstein <a href=\"https://thefly.com/thestreet/realmoney/index.php/CFid3004525/CF-CF-Industries-downgraded-at-Bernstein-on-declining-Chinese-coal-prices\" target=\"_blank\">downgrades</a> shares to Underperform  from Market Perform with a $37 price target, citing its expectation of lower nitrogen prices, driven by falling Chinese coal  prices.</li><li>Bernstein's Jonas Oxgaard says he shares the consensus  view that demand should be strong in 2020 but does not believe this  additional demand will move the intercept on the cost curve enough to  offset the declining coal price.</li><li>CF's average <a href=\"https://seekingalpha.com/symbol/CF/ratings/sell-side-ratings\" target=\"_blank\">Sell Side Ratin</a>g and <a href=\"https://seekingalpha.com/symbol/CF/ratings/author-ratings#filter=all\" target=\"_blank\">Seeking Alpha Authors' Rating</a> are both Bullish, while its <a href=\"https://seekingalpha.com/symbol/CF/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> is Neutral.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525224\" data-linked=\"CF cut to Sell equivalent at Bernstein on falling Chinese coal prices\" data-tweet=\"$CF - CF cut to Sell equivalent at Bernstein on falling Chinese coal prices https://seekingalpha.com/news/3525224-cf-cut-to-sell-equivalent-bernstein-on-falling-chinese-coal-prices?source=tweet\" data-url=\"https://seekingalpha.com/news/3525224-cf-cut-to-sell-equivalent-bernstein-on-falling-chinese-coal-prices\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525216\" data-ts=\"1575997236\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MGTA\" target=\"_blank\">MGTA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525216-magenta-up-15-on-promising-data-on-adc-conditioning-agent\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Magenta up 15% on promising data on ADC conditioning agent</a></h4><ul><li>Thinly traded Magenta Therapeutics (<a href='https://seekingalpha.com/symbol/MGTA' title='Magenta Therapeutics, Inc.'>MGTA</a> <font color=\"green\">+14.7%</font>) is up more than double normal volume, albeit on turnover of only 211K shares, on the heels of encouraging <a href=\"https://seekingalpha.com/pr/17721693-magenta-therapeutics-demonstrates-first-ever-successful-gene-therapy-transplant-without\" target=\"_blank\">preclinical data</a> on CD117-ADC, its most advanced program for the preparation of patients undergoing stem cell transplantation or gene therapy. The results were presented yesterday at ASH in Orlando.</li><li>An NIH scientist presented data that showed the first-ever successful transplant of gene-modified cells in non-human primates without chemo or radiation preconditioning via the use of a targeted single-agent antibody-drug conjugate &#40;ADC&#41;. Chemo and radiation are typically used to kill disease-causing cells before treatment, a paradigm saddled with severe side effects like toxicity and infertility.</li><li>A single dose of CD117-ADC achieved the same level of depletion as four doses of chemo agent busulfan, enabling the successful engraftment and persistence of stem cells with the β-globin gene, mutations of which cause sickle cell disease and β-thalassemia, without the toxic side effects. Vector copy number was stable beyond three months.</li><li>The single dose of CD117-ADC depleted hematopoietic stem cells in the animals while sparing immune cells.</li><li>#ASH19</li></ul><div class=\"tiny-share-widget\" data-id=\"3525216\" data-linked=\"Magenta up 15% on promising data on ADC conditioning agent\" data-tweet=\"$MGTA - Magenta up 15% on promising data on ADC conditioning agent https://seekingalpha.com/news/3525216-magenta-up-15-on-promising-data-on-adc-conditioning-agent?source=tweet\" data-url=\"https://seekingalpha.com/news/3525216-magenta-up-15-on-promising-data-on-adc-conditioning-agent\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525215\" data-ts=\"1575997190\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525215-electrameccanica-vehicles-leads-consumer-gainers-pyxus-international-in-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Electrameccanica Vehicles leads consumer gainers; Pyxus International in losers</a></h4><ul><li><b>Gainers: </b>Electrameccanica Vehicles (NASDAQ:<a href='https://seekingalpha.com/symbol/SOLO' title='Electrameccanica Vehicles Corp.'>SOLO</a>) <font color=\"green\">+14%</font>. DAVIDsTEA (NASDAQ:<a href='https://seekingalpha.com/symbol/DTEA' title='DAVIDsTEA Inc.'>DTEA</a>) <font color=\"green\">+8%</font>. Nautilus (NYSE:<a href='https://seekingalpha.com/symbol/NLS' title='Nautilus, Inc.'>NLS</a>) <font color=\"green\">+7%</font>. Adecoagro (NYSE:<a href='https://seekingalpha.com/symbol/AGRO' title='Adecoagro S.A.'>AGRO</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers: </b>Unique Fabricating (NYSEMKT:<a href='https://seekingalpha.com/symbol/UFAB' title='Unique Fabricating, Inc.'>UFAB</a>) <font color=\"red\">-6%</font>. Pyxus International (NYSE:<a href='https://seekingalpha.com/symbol/PYX' title='Pyxus International, Inc.'>PYX</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525215\" data-linked=\"Electrameccanica Vehicles leads consumer gainers; Pyxus International in losers\" data-tweet=\"$SOLO $DTEA $NLS - Electrameccanica Vehicles leads consumer gainers; Pyxus International in losers https://seekingalpha.com/news/3525215-electrameccanica-vehicles-leads-consumer-gainers-pyxus-international-in-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3525215-electrameccanica-vehicles-leads-consumer-gainers-pyxus-international-in-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:59 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525206\" data-ts=\"1575995497\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRTY\" target=\"_blank\">PRTY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525206-investors-nibble-party-city\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Investors nibble at Party City</a></h4><ul> <li>Party City (<a href='https://seekingalpha.com/symbol/PRTY' title='Party City Holdco Inc.'>PRTY</a> <font color='green'>+7.6%</font>) is <font color=\"green\">up 7.66%</font> as shares continue to slowly bounce off their 52-week low from a few weeks ago and cut into the staggering 80% YTD drop.</li><li>Volume on Party City today is already over 4M shares to top the normal amount of activity.</li> <li>The November swoon for the retailer was tied in part to a third consecutive Halloween period of lower sales and the continued impact of the helium shortage.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3525206\" data-linked=\"Investors nibble at Party City\" data-tweet=\"$PRTY - Investors nibble at Party City https://seekingalpha.com/news/3525206-investors-nibble-party-city?source=tweet\" data-url=\"https://seekingalpha.com/news/3525206-investors-nibble-party-city\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525204\" data-ts=\"1575994997\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NSPR\" target=\"_blank\">NSPR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525204-inspiremd-chief-to-step-down-shares-up-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">InspireMD chief to step down; shares up 3%</a></h4><ul><li>InspireMD (<a href='https://seekingalpha.com/symbol/NSPR' title='InspireMD, Inc.'>NSPR</a> <font color=\"green\">+2.8%</font>) President &amp; CEO James Barry, Ph.D., is <a href=\"https://seekingalpha.com/pr/17723211-inspiremd-announces-planned-leadership-transition\" target=\"_blank\">resigning</a> to pursue other opportunities. Marvin Slosman will succeed him effective January 1, 2020.</li><li>Previously, Mr. Slosman consulted at Integra LifeSciences overseeing commercial strategy and international market development.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525204\" data-linked=\"InspireMD chief to step down; shares up 3%\" data-tweet=\"$NSPR - InspireMD chief to step down; shares up 3% https://seekingalpha.com/news/3525204-inspiremd-chief-to-step-down-shares-up-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3525204-inspiremd-chief-to-step-down-shares-up-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:23 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525202\" data-ts=\"1575994620\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SAGE\" target=\"_blank\">SAGE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525202-sage-therapeutics-to-advance-huntingtons-candidate-sageminus-718-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sage Therapeutics to advance Huntington&#39;s candidate SAGE-718; shares up 2%</a></h4><ul><li>Citing encouraging Phase 1 data, Sage Therapeutics (<a href='https://seekingalpha.com/symbol/SAGE' title='Sage Therapeutics, Inc.'>SAGE</a> <font color=\"green\">+1.6%</font>) plans to advance allosteric NMDA receptor modulator SAGE-718 to Phase 2 for the treatment of <a href=\"https://www.mayoclinic.org/diseases-conditions/huntingtons-disease/symptoms-causes/syc-20356117\" target=\"_blank\">Huntington's disease</a> &#40;HD&#41;, an inherited disorder in which nerve cells in the brain progressively degrade resulting in uncontrollable movements in the limbs, face and upper body in addition to cognitive and psychiatric problems.</li><li>Results from a 14-day open-label Phase 1 showed a favorable safety, tolerability and pharmacokinetic profile and improved performance in six HD patients who received daily doses of SAGE-718. Additional data will be presented at a medical conference in 2020.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525202\" data-linked=\"Sage Therapeutics to advance Huntington&#39;s candidate SAGE-718; shares up 2%\" data-tweet=\"$SAGE - Sage Therapeutics to advance Huntington&#39;s candidate SAGE-718; shares up 2% https://seekingalpha.com/news/3525202-sage-therapeutics-to-advance-huntingtons-candidate-sageminus-718-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3525202-sage-therapeutics-to-advance-huntingtons-candidate-sageminus-718-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525199\" data-ts=\"1575994185\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TENB\" target=\"_blank\">TENB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525199-cowen-sees-upside-in-tenbs-indegy-purchase\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cowen sees upside in TENB&#39;s Indegy purchase</a></h4><ul><li>Cowen analyst Nick Yako says Tenable's (<a href='https://seekingalpha.com/symbol/TENB' title='Tenable Holdings, Inc.'>TENB</a> <font color='red'>-1.4%</font>) <a href=\"https://seekingalpha.com/news/3523336-tenable-scoops-up-indegy-for-78m\" target=\"_blank\">recent acquisition</a> of Indegy could \"prove to be a source of upside\" to current estimates.</li><li>The purchase should strengthen TENB's position in the operational technology security market, which is expected to surpass $1B by 2022 for a CAGR of 40%+ from 2019-22.</li><li>Cowen maintains an Outperform rating and $36 price target. TENB has a Bullish average <a href=\"https://seekingalpha.com/symbol/TENB/ratings/sell-side-ratings\" target=\"_blank\">Sell Side rating</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525199\" data-linked=\"Cowen sees upside in TENB&#39;s Indegy purchase\" data-tweet=\"$TENB - Cowen sees upside in TENB&#39;s Indegy purchase https://seekingalpha.com/news/3525199-cowen-sees-upside-in-tenbs-indegy-purchase?source=tweet\" data-url=\"https://seekingalpha.com/news/3525199-cowen-sees-upside-in-tenbs-indegy-purchase\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525194\" data-ts=\"1575993697\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525194-healthcare-top-5-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers</a></h4><ul><li><b>Gainers: </b>Neoleukin Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/NLTX' title='Neoleukin Therapeutics, Inc.'>NLTX</a>) <font color=\"green\">+33%</font>. Iterum Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ITRM' title='Iterum Therapeutics plc'>ITRM</a>) <font color=\"green\">+22%</font>. Equillium (NASDAQ:<a href='https://seekingalpha.com/symbol/EQ' title='Equillium, Inc.'>EQ</a>) <font color=\"green\">+19%</font>. Kiniksa Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/KNSA' title='Kiniksa Pharmaceuticals, Ltd.'>KNSA</a>) <font color=\"green\">+16%</font>. Avid Bioservices (NASDAQ:<a href='https://seekingalpha.com/symbol/CDMO' title='Avid Bioservices, Inc.'>CDMO</a>) <font color=\"green\">+16%</font>.</li><li><b>Losers: </b>Achieve Life Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/ACHV' title='Achieve Life Sciences, Inc.'>ACHV</a>) <font color=\"red\">-14%</font>. Beyond Air (NASDAQ:<a href='https://seekingalpha.com/symbol/XAIR' title='Beyond Air, Inc.'>XAIR</a>) <font color=\"red\">-11%</font>. Livongo Health (NASDAQ:<a href='https://seekingalpha.com/symbol/LVGO' title='Livongo Health, Inc.'>LVGO</a>) <font color=\"red\">-9%</font>. Taronis Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/TRNX' title='Taronis Technologies, Inc.'>TRNX</a>) <font color=\"red\">-8%</font>. XBiotech (NASDAQ:<a href='https://seekingalpha.com/symbol/XBIT' title='XBiotech Inc.'>XBIT</a>) <font color=\"red\">-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525194\" data-linked=\"Healthcare - Top 5 Gainers / Losers\" data-tweet=\"$NLTX $ITRM $EQ - Healthcare - Top 5 Gainers / Losers https://seekingalpha.com/news/3525194-healthcare-top-5-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3525194-healthcare-top-5-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525189\" data-ts=\"1575993288\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EGRX\" target=\"_blank\">EGRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525189-eagle-pharma-set-to-refile-ryanodex-nda-shares-ahead-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eagle Pharma set to refile Ryanodex NDA; shares ahead 5%</a></h4><ul><li>In a regulatory filing, Eagle Pharmaceuticals (<a href='https://seekingalpha.com/symbol/EGRX' title='Eagle Pharmaceuticals, Inc.'>EGRX</a> <font color=\"green\">+5.2%</font>) <a href=\"https://www.sec.gov/ix?doc=/Archives/edgar/data/827871/000110465919071175/tm1924618d1_8k.htm\" target=\"_blank\">discloses </a>that it expects to resubmit its U.S. marketing application for Ryanodex (dantrolene sodium) for the treatment of exertional heat stroke \"shortly.\"</li><li>The company <a href=\"https://seekingalpha.com/news/3281569-fda-rejects-eagle-pharmaceuticals-marketing-application-for-heat-stroke-med-ryanodex-trading\" target=\"_blank\">received a CRL</a> in July 2017 citing the need for an additional clinical trial. In its <a href=\"https://seekingalpha.com/pr/17695011-eagle-pharmaceuticals-reports-third-quarter-2019-results\" target=\"_blank\">Q3 earnings press release</a>, it stated that it planned to seek FDA sign-off on the adequacy of data on 41 people who participated in Hajj pilgrimages in 2015, 2018 and 2019. Target enrollment for the <a href=\"https://clinicaltrials.gov/ct2/show/NCT03600376?lead=eagle+pharmaceuticals&amp;phase=2&amp;draw=2&amp;rank=1\" target=\"_blank\">Phase 3 study</a> launched in August 2018 was 100. The estimated completion date was August of this year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525189\" data-linked=\"Eagle Pharma set to refile Ryanodex NDA; shares ahead 5%\" data-tweet=\"$EGRX - Eagle Pharma set to refile Ryanodex NDA; shares ahead 5% https://seekingalpha.com/news/3525189-eagle-pharma-set-to-refile-ryanodex-nda-shares-ahead-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3525189-eagle-pharma-set-to-refile-ryanodex-nda-shares-ahead-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:54 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525191\" data-ts=\"1575993256\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BPOP\" target=\"_blank\">BPOP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525191-popular-to-review-letter-from-activist-investor\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Popular to review letter from activist investor</a></h4><ul><li>Popular Inc. (<a href='https://seekingalpha.com/symbol/BPOP' title='Popular, Inc.'>BPOP</a> <font color='green'>+1.6%</font>) says it <a href=\"https://seekingalpha.com/pr/17723951-popular-inc-statement-on-raging-capital-management-letter-to-board-of-directors\" target=\"_blank\">will review a</a>n open letter sent to the company's board by activist investor Raging Capital Management, which seeks actions to increase shareholder value.</li><li>\"Popular always seeks to maintain an open and constructive dialogue with its shareholders,\" the company said in a statement.</li><li>Raging Capital, which owns ~700K of Popular's common shares, <a href=\"https://seekingalpha.com/pr/17722567-raging-capital-delivers-letter-to-popular-inc-board-of-directors\" target=\"_blank\">calls on the board</a> to hire an investment banking firm to \"explore all strategic alternatives,\" including a spinoff of BPOP's 16% stake in Evertec; a spinoff and/or merger of BPOP's mainland U.S. subsdiary; or the sale of the entire company.</li><li>The investor also wants the board to start a stock repurchase program of at least $1B and to double the current dividend payout ratios.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525191\" data-linked=\"Popular to review letter from activist investor\" data-tweet=\"$BPOP - Popular to review letter from activist investor https://seekingalpha.com/news/3525191-popular-to-review-letter-from-activist-investor?source=tweet\" data-url=\"https://seekingalpha.com/news/3525191-popular-to-review-letter-from-activist-investor\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:54 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525190\" data-ts=\"1575993227\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QTT\" target=\"_blank\">QTT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525190-qutoutiao-slides-after-short-seller-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Qutoutiao slides after short-seller report</a></h4><ul><li>Qutoutiao (<a href='https://seekingalpha.com/symbol/QTT' title='Qutoutiao Inc.'>QTT</a> <font color='red'>-3.2%</font>) shares drop after a cautious mention from <a href=\"https://wolfpackresearch.com/qtt-fakerevenues-fakecash-undisclosedrelatedparties/\" target=\"_blank\">Wolfpack Research</a>.</li><li>Wolfpack calls QTT a \"low-tech, cash incinerating malware distributor\" and says that the \"vast majority of QTT\u2019s revenue is generated solely by the accounting department.\"</li><li>Key quote: \"We conclude that QTT exists to enrich its Founder and CEO, Eric Tan, and promote his VC fund\u2019s other ventures by creating its own in-house 'advertising agent' in order to direct significant amounts of ad traffic to undisclosed related parties owned by Tan.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3525190\" data-linked=\"Qutoutiao slides after short-seller report\" data-tweet=\"$QTT - Qutoutiao slides after short-seller report https://seekingalpha.com/news/3525190-qutoutiao-slides-after-short-seller-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3525190-qutoutiao-slides-after-short-seller-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:53 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525188\" data-ts=\"1575992924\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DVN\" target=\"_blank\">DVN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525188-devon-energy-dow-to-jointly-develop-oklahoma-shale-acreage\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Devon Energy, Dow to jointly develop Oklahoma shale acreage</a></h4><ul><li>Devon Energy (<a href='https://seekingalpha.com/symbol/DVN' title='Devon Energy Corporation'>DVN</a> <font color='green'>+2.4%</font>) and Dow Inc. (<a href='https://seekingalpha.com/symbol/DOW' title='Dow Inc.'>DOW</a> <font color='red'>-0.1%</font>) announce plans to <a href=\"https://seekingalpha.com/pr/17723074-devon-energy-announces-agreement-dow-to-develop-stack-acreage\" target=\"_blank\">jointly develop</a> some of DVN's STACK acreage in Oklahoma, starting next year with the development of two drilling units in northern Canadian County.</li><li>Under the JV agreement, DVN says it will monetize half of its working interest in 133 undrilled locations in exchange for a ~$100M drilling  carry over the next four years.</li><li>DVN, who will serve as operator of the JV, says it will retain 100% of its production and cash flow from existing operations in the STACK play.</li><li>The agreement is a \"mild positive but not a significant needle-mover,\" says Capital One analyst Phillips Johnston, adding that the move is not a total surprise as DVN had signaled previously it was looking into JV opportunities in the STACK play.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525188\" data-linked=\"Devon Energy, Dow to jointly develop Oklahoma shale acreage\" data-tweet=\"$DVN $DOW - Devon Energy, Dow to jointly develop Oklahoma shale acreage https://seekingalpha.com/news/3525188-devon-energy-dow-to-jointly-develop-oklahoma-shale-acreage?source=tweet\" data-url=\"https://seekingalpha.com/news/3525188-devon-energy-dow-to-jointly-develop-oklahoma-shale-acreage\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525187\" data-ts=\"1575992796\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525187-comcast-sues-l3harris-in-patent-dispute\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Comcast sues L3Harris in patent dispute</a></h4><ul>   <li>Comcast (<a href=\"http://seekingalpha.com/symbol/CMCSA\" target=\"_blank\">CMCSA</a> <font color=\"red\">-2.1%</font>) has sued L3Harris (<a href=\"http://seekingalpha.com/symbol/LHX\" target=\"_blank\">LHX</a> <font color=\"green\">+1.9%</font>) over demands for patent royalties, asking a court to declare that it doesn't owe anything, Bloomberg reports.</li>    <li>The cableco says L3Harris lawyers are claiming more than a dozen of its patents cover aspects of Zigbee, Bluetooth Low Energy, 802.11 and Thread standards, all used in Internet of Things devices.</li>    <li>Now after an \"extended dialogue\" over licensing, Comcast says it doesn't practice L3Harris' patents and doesn't need to execute any license.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3525187\" data-linked=\"Comcast sues L3Harris in patent dispute\" data-tweet=\"$CMCSA $LHX - Comcast sues L3Harris in patent dispute https://seekingalpha.com/news/3525187-comcast-sues-l3harris-in-patent-dispute?source=tweet\" data-url=\"https://seekingalpha.com/news/3525187-comcast-sues-l3harris-in-patent-dispute\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525184\" data-ts=\"1575992164\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FIZZ\" target=\"_blank\">FIZZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525184-national-beverageplus-4-analysts-keep-scrambling\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">National Beverage +4% as analysts keep scrambling</a></h4><ul> <li>National Beverage (NASDAQ:<a href='https://seekingalpha.com/symbol/FIZZ' title='National Beverage Corp.'>FIZZ</a>) rallies after UBS hikes its price target on the Neutral-rated beverage stock to $57 from $44.</li> <li>The average sell-side PT on National Beverage is $45.75, a level which the stock has blown right past.</li> <li>Shares of NBEV are <font color=\"green\">up 3.95%</font> on the day and are now up 37% over the last four weeks.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3525184\" data-linked=\"National Beverage +4% as analysts keep scrambling\" data-tweet=\"$FIZZ - National Beverage +4% as analysts keep scrambling https://seekingalpha.com/news/3525184-national-beverageplus-4-analysts-keep-scrambling?source=tweet\" data-url=\"https://seekingalpha.com/news/3525184-national-beverageplus-4-analysts-keep-scrambling\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525176\" data-ts=\"1575991612\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ITCI\" target=\"_blank\">ITCI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525176-intra-cellular-up-10-ahead-of-presentation-of-lumateperone-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intra-Cellular up 10% ahead of presentation of lumateperone data</a></h4><ul><li>Intra-Cellular Therapies (<a href='https://seekingalpha.com/symbol/ITCI' title='Intra-Cellular Therapies, Inc.'>ITCI</a> <font color=\"green\">+10%</font>) perks up on modestly higher volume ahead of a <a href=\"https://seekingalpha.com/pr/17717833-intra-cellular-therapies-to-present-data-on-lumateperone-and-itiminus-333-58th-annual-meeting\" target=\"_blank\">presentation </a>of lumateperone data tomorrow at the American College of Neuropsychopharmacology Annual Meeting in Hollywood, FL.</li><li>Results from a Phase 3 study in bipolar depression, pooled data in schizophrenia and results from a 12-month safety study will be presented at 5:30 pm ET.</li><li>The FDA's action date for the company's application seeking approval of lumateperone for schizophrenia is Friday, December 27.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525176\" data-linked=\"Intra-Cellular up 10% ahead of presentation of lumateperone data\" data-tweet=\"$ITCI - Intra-Cellular up 10% ahead of presentation of lumateperone data https://seekingalpha.com/news/3525176-intra-cellular-up-10-ahead-of-presentation-of-lumateperone-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3525176-intra-cellular-up-10-ahead-of-presentation-of-lumateperone-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525169\" data-ts=\"1575991066\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DERM\" target=\"_blank\">DERM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525169-dermiras-lebrikizumab-fast-trackd-for-atopic-dermatitis-shares-up-12\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dermira&#39;s lebrikizumab Fast Track&#39;d for atopic dermatitis; shares up 12%</a></h4><ul><li>Dermira (<a href='https://seekingalpha.com/symbol/DERM' title='Dermira, Inc.'>DERM</a> <font color=\"green\">+12.3%</font>) is up on modestly higher volume in reaction to <a href=\"https://seekingalpha.com/pr/17723403-dermira-receives-fast-track-designation-from-fda-for-lebrikizumab-for-treatment-of-atopic\" target=\"_blank\">Fast Track status</a> in the U.S. for IL-13 inhibitor lebrikizumab for the treatment of atopic dermatitis.</li><li>Two Phase 3 studies, <a href=\"https://clinicaltrials.gov/ct2/show/NCT04146363?lead=dermira&amp;phase=2&amp;draw=2&amp;rank=2\" target=\"_blank\">ADvocate 1</a> and <a href=\"https://clinicaltrials.gov/ct2/show/NCT04178967?lead=dermira&amp;phase=2&amp;draw=2&amp;rank=1\" target=\"_blank\">ADvocate 2</a>, are in process.</li><li>Fast Track provides for more frequent interaction with the FDA review team and a rolling review of the marketing application.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525169\" data-linked=\"Dermira&#39;s lebrikizumab Fast Track&#39;d for atopic dermatitis; shares up 12%\" data-tweet=\"$DERM - Dermira&#39;s lebrikizumab Fast Track&#39;d for atopic dermatitis; shares up 12% https://seekingalpha.com/news/3525169-dermiras-lebrikizumab-fast-trackd-for-atopic-dermatitis-shares-up-12?source=tweet\" data-url=\"https://seekingalpha.com/news/3525169-dermiras-lebrikizumab-fast-trackd-for-atopic-dermatitis-shares-up-12\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:17 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525167\" data-ts=\"1575990981\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDB\" target=\"_blank\">MDB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525167-mongodb-bull-says-earnings-eased-concerns\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MongoDB bull says earnings eased concerns</a></h4><ul><li>MongoDB (<a href='https://seekingalpha.com/symbol/MDB' title='MongoDB, Inc.'>MDB</a> <font color='green'>+5.9%</font>) shares continue to see green after yesterday's <a href=\"https://seekingalpha.com/news/3524948-mongodbplus-7_6-after-q3-beat-strong-guidance\" target=\"_blank\">Q3 beat</a> and strong guidance.</li><li>Citi (Buy rating) says that the report \"shakes off concerns of decelerating growth,\" praising the 10% revenue upside, positive billings performance, and 4% revenue guidance upside.</li><li>The firm expects a positive reaction to the print due to the recent underperformance and concerns about diminishing returns and decelerating growth.</li><li>MongoDB has a Bullish average <a href=\"https://seekingalpha.com/symbol/MDB/ratings/sell-side-ratings\" target=\"_blank\">Sell Side rating</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525167\" data-linked=\"MongoDB bull says earnings eased concerns\" data-tweet=\"$MDB - MongoDB bull says earnings eased concerns https://seekingalpha.com/news/3525167-mongodb-bull-says-earnings-eased-concerns?source=tweet\" data-url=\"https://seekingalpha.com/news/3525167-mongodb-bull-says-earnings-eased-concerns\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525157\" data-ts=\"1575989874\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BLUE\" target=\"_blank\">BLUE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525157-bluebird-bio-up-3-on-updated-car-t-candidate-bb21217-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bluebird bio up 3% on updated CAR T candidate bb21217 data</a></h4><ul><li>Bluebird bio (<a href='https://seekingalpha.com/symbol/BLUE' title='bluebird bio, Inc.'>BLUE</a> <font color=\"green\">+3%</font>) and collaboration partner Bristol-Myers Squibb (<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a> <font color=\"green\">+0.5%</font>) (via its acquisition of Celgene) announce <a href=\"https://seekingalpha.com/pr/17722771-bluebird-bio-and-bristol-myers-squibb-present-updated-data-from-ongoing-phase-1-study-of-bcma\" target=\"_blank\">updated results</a> from a two-part open-label Phase 1 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03274219?intr=bb21217&amp;phase=01&amp;rank=1\" target=\"_blank\">CRB-402</a>, evaluating BCMA-targeted CAR T candidate bb21217 in heavily pretreated patients with relapsed/refractory multiple myeloma &#40;MM&#41;, a population with a poor prognosis. The data were presented at ASH in Orlando.</li><li>The dose-escalation portion (three dose levels) is finished. The dose-expansion phase is in process. Final enrollment should be 74 subjects.</li><li>12 patients in the 150 x 10<sup>6</sup> CAR+ T cells arm (the lowest dose) were evaluable. Mean follow-up was 17.6 months. 83% (n=10/12) showed clinical response, including four complete responders and six with very good partial responses. Median duration of response was 11.1 months.</li><li>As of the data cutoff, follow-up was still early in the other dose arms (300 x 10<sup>6</sup> CAR+ T cells and 450 x 10<sup>6</sup> CAR+ T cells) but no confirmed responders have progressed. The response rate in the 300 group was 43% (n=6/14), none complete, and 57% (n=4/7) in the 450 group with one complete responder. Median follow-up periods were 4.0 months and 3.3 months, respectively.</li><li>On the safety front, the most frequent serious/life-threatening adverse events in 38 treated patients were neutropenia (82%), leukopenia (55%), thrombocytopenia (55%), anemia (50%), lymphopenia (34%), hypophosphatemia (21%), hyponatremia (13%) and febrile neutropenia (11%). Seven patients experienced serious/life-threatening infections.</li><li>66% (n=25/38) developed bb21217-related cytokine release syndrome &#40;CRS&#41;, most mild or moderate. There was one case of serious CRS and one death (in the 450 arm after 15 days of follow-up). 24% (n=9/38) developed neurotoxicity, two serious and one life-threatening (encephalopathy).</li><li>The estimated completion date is January 2025.</li><li>#ASH19</li></ul><div class=\"tiny-share-widget\" data-id=\"3525157\" data-linked=\"Bluebird bio up 3% on updated CAR T candidate bb21217 data\" data-tweet=\"$BLUE $BMY - Bluebird bio up 3% on updated CAR T candidate bb21217 data https://seekingalpha.com/news/3525157-bluebird-bio-up-3-on-updated-car-t-candidate-bb21217-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3525157-bluebird-bio-up-3-on-updated-car-t-candidate-bb21217-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525156\" data-ts=\"1575989764\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LHX\" target=\"_blank\">LHX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525156-l3harrisplus-2_4-bernstein-starts-outperform\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">L3Harris +2.4% as Bernstein starts at Outperform</a></h4><ul>   <li>L3Harris (NYSE:<a href='https://seekingalpha.com/symbol/LHX' title='L3Harris Technologies, Inc.'>LHX</a>) is <font color=\"green\">up 2.4%</font> this morning as Bernstein launched coverage at Outperform.</li>    <li>The stock looks good after recent weeks' pullback, the firm says, and notes it expects free cash flow to come in at $3.47B next year, above the $3B guidance and consensus.</li>    <li>It's got a price target of $247, implying 25% upside.</li>    <li>Bernstein's in good company on the Street: Sell-side analysts are <a href=\"https://seekingalpha.com/symbol/LHX/ratings/sell-side-ratings\" target=\"_blank\">Bullish on the stock</a>, as are <a href=\"https://seekingalpha.com/symbol/LHX/ratings/author-ratings\" target=\"_blank\">Seeking Alpha authors</a>. It has a <a href=\"https://seekingalpha.com/symbol/LHX/ratings/quant-ratings\" target=\"_blank\">Quant Rating of Neutral</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3525156\" data-linked=\"L3Harris +2.4% as Bernstein starts at Outperform\" data-tweet=\"$LHX - L3Harris +2.4% as Bernstein starts at Outperform https://seekingalpha.com/news/3525156-l3harrisplus-2_4-bernstein-starts-outperform?source=tweet\" data-url=\"https://seekingalpha.com/news/3525156-l3harrisplus-2_4-bernstein-starts-outperform\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:56 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525150\" data-ts=\"1575989116\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TOL\" target=\"_blank\">TOL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525150-toll-brothersminus-3_7-q1-outlook-disappoints\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Toll Brothers -3.7% as Q1 outlook disappoints</a></h4><ul><li>Toll Brothers (NYSE:<a href='https://seekingalpha.com/symbol/TOL' title='Toll Brothers, Inc.'>TOL</a>) <font color=\"red\">slides 3.7%</font> after analysts flag lower-than-expected Q1 2020 guidance from the homebuilder.</li><li>Raymond James analyst Buck Horne writes, \"The most pressing issue appears to be Toll's adjusted gross margin guidance of ~21.3%\" - an almost 300 bps Y/Y decline and \"well below our published 23.5% estimate.\"</li><li>JPMorgan's Michael Rehaut notes that Q4 order growth \"was below our estimate and we believe investor expectations.</li><li>He also points out that Q1 gross margin guidance of 21.25% slips from Q4's 21.9%; by comparison, other builders' calendar Q4 gross margins are expected to be flat to up slightly.</li><li>KBW's Jade Rahmani writes that while Q1 guidance is below KBW's estimate and the consensus forecast, strengthening demand in the first six weeks of fiscal Q1 \"should benefit margins going forward.\"</li><li><a href=\"https://seekingalpha.com/symbol/TOL/ratings/quant-ratings\" target=\"_blank\">Quant rating</a> Neutral; <a href=\"https://seekingalpha.com/symbol/TOL/ratings/sell-side-ratings\" target=\"_blank\">Sell-Side average rating</a> Neutral (1 Very Bullish, 1 Bullish, 16 Neutral, 2 Bearish).</li><li>Toll Brothers<a href=\"https://investors.tollbrothers.com/news-and-events/events-and-presentations\" target=\"_blank\"> conference call</a> at 11:00 AM ET.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3524959-toll-brothers-q4-eps-beats-sees-stronger-demand-in-q1\" target=\"_blank\">Toll Brothers Q4 EPS beats; sees stronger demand in Q1</a> (Dec. 9)</li></ul><div class=\"tiny-share-widget\" data-id=\"3525150\" data-linked=\"Toll Brothers -3.7% as Q1 outlook disappoints\" data-tweet=\"$TOL - Toll Brothers -3.7% as Q1 outlook disappoints https://seekingalpha.com/news/3525150-toll-brothersminus-3_7-q1-outlook-disappoints?source=tweet\" data-url=\"https://seekingalpha.com/news/3525150-toll-brothersminus-3_7-q1-outlook-disappoints\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525136\" data-ts=\"1575987827\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525136-mdb-gnw-among-premarket-gainer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MDB, GNW among premarket gainer</a></h4><ul><li>Technical Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/TCCO' title='Technical Communications Corporation'>TCCO</a>) <font color=\"green\">+260%</font> after <a href=\"https://seekingalpha.com/news/3524979-technical-communications-reports-q4-results\" target=\"_blank\">Q4 results</a>.</li><li>Equillium (NASDAQ:<a href='https://seekingalpha.com/symbol/EQ' title='Equillium, Inc.'>EQ</a>) <font color=\"green\">+19%</font> as <a href=\"https://seekingalpha.com/news/3524940-equilliums-itolizumab-fast-trackd-for-lupus-nephritis\" target=\"_blank\">itolizumab Fast Track'd</a> for lupus nephritis.</li><li>CounterPath (NASDAQ:<a href='https://seekingalpha.com/symbol/CPAH' title='CounterPath Corporation'>CPAH</a>) <font color=\"green\">+14%</font> on the <a href=\"https://seekingalpha.com/pr/17723511-counterpath-launches-bria-solo-extending-business-class-calling-on-desktop-and-mobile-devices\" target=\"_blank\">launch</a> of Bria Solo.</li><li>ObsEva SA (NASDAQ:<a href='https://seekingalpha.com/symbol/OBSV' title='ObsEva SA'>OBSV</a>) <font color=\"green\">+13%</font> on <a href=\"https://seekingalpha.com/news/3524726-obseva-up-26-premarket-on-positive-linzagolix-data\" target=\"_blank\">positive linzagolix data</a>.</li><li>LMP Automotive Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/LMPX' title='LMP Automotive Holdings, Inc.'>LMPX</a>) <font color=\"green\">+10%</font>.</li><li>Genworth Financial (NYSE:<a href='https://seekingalpha.com/symbol/GNW' title='Genworth Financial, Inc.'>GNW</a>) <font color=\"green\">+11%</font> as Brookfield Business <a href=\"https://seekingalpha.com/news/3524963-brookfield-business-gets-canadas-okay-on-genworth-mi-canada-deal\" target=\"_blank\">gets Canada's okay</a> on Genworth MI Canada deal.</li><li>Stitch Fix (NASDAQ:<a href='https://seekingalpha.com/symbol/SFIX' title='Stitch Fix, Inc.'>SFIX</a>) <font color=\"green\">+9%</font> after <a href=\"https://seekingalpha.com/symbol/SFIX?s=tco\" target=\"_blank\">Q1 results</a>.</li><li>MongoDB (NASDAQ:<a href='https://seekingalpha.com/symbol/MDB' title='MongoDB, Inc.'>MDB</a>) <font color=\"green\">+8%</font> after <a href=\"https://seekingalpha.com/news/3524919-mongodb-eps-beats-0_02-beats-on-revenue\" target=\"_blank\">Q3 results</a>.</li><li>Dermira (NASDAQ:<a href='https://seekingalpha.com/symbol/DERM' title='Dermira, Inc.'>DERM</a>) <font color=\"green\">+8%</font> on <a href=\"https://seekingalpha.com/pr/17723403-dermira-receives-fast-track-designation-from-fda-for-lebrikizumab-for-treatment-of-atopic\" target=\"_blank\">receiving</a> fast track designation from FDA for Lebrikizumab for the treatment of atopic dermatitis.</li><li>Avid Bioservices (NASDAQ:<a href='https://seekingalpha.com/symbol/CDMO' title='Avid Bioservices, Inc.'>CDMO</a>) <font color=\"green\">+8%</font> after <a href=\"https://seekingalpha.com/news/3524927-avid-bioservices-eps-beats-0_03-beats-on-revenue\" target=\"_blank\">Q2 results</a>.</li><li>Sibanye Gold (NYSE:<a href='https://seekingalpha.com/symbol/SBGL' title='Sibanye Gold Limited'>SBGL</a>) <font color=\"green\">+6%</font>.</li><li>Precision BioSciences (NASDAQ:<a href='https://seekingalpha.com/symbol/DTIL' title='Precision BioSciences, Inc.'>DTIL</a>) <font color=\"green\">+5%</font>.</li><li>Forty Seven (NASDAQ:<a href='https://seekingalpha.com/symbol/FTSV' title='Forty Seven, Inc.'>FTSV</a>) <font color=\"green\">+6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525136\" data-linked=\"MDB, GNW among premarket gainer\" data-tweet=\"$TCCO $EQ $CPAH - MDB, GNW among premarket gainer https://seekingalpha.com/news/3525136-mdb-gnw-among-premarket-gainer?source=tweet\" data-url=\"https://seekingalpha.com/news/3525136-mdb-gnw-among-premarket-gainer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525134\" data-ts=\"1575987627\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SUPN\" target=\"_blank\">SUPN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525134-supernus-pharma-up-10-premarket-on-updated-late-stage-spnminus-810-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Supernus Pharma up 10% premarket on updated late-stage SPN-810 results</a></h4><ul><li>Supernus Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/SUPN' title='Supernus Pharmaceuticals, Inc.'>SUPN</a>) is up <font color=\"green\">10%</font> premarket on light volume in reaction to <a href=\"https://seekingalpha.com/pr/17722628-supernus-provides-update-on-results-from-phase-iii-study-p301-of-spnminus-810-for-treatment\" target=\"_blank\">updated data</a> from a Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02618408?intr=spn-810&amp;lead=supernus&amp;phase=2&amp;draw=2&amp;rank=3\" target=\"_blank\">P301</a>, evaluating SPN-810 for the treatment of impulsive aggression &#40;IA&#41; in patients (ages 6 - 11 years) with attention deficit hyperactivity disorder &#40;ADHD&#41;.</li><li>Topline results, first reported last month, showed a median 58.6% reduction in average weekly frequency of IA episodes from baseline compared to placebo. The separation, however, was not statistically significant (p=0.092).</li><li>The issue was an increase in variability in the 36 mg treatment arm due to six participants (out of 135) with mild IA conditions (seven with same were in the control arm). Excluding these, the separation was statistically valid (p=0.017).</li><li>Results from a second Phase 3, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02618434?intr=spn-810&amp;lead=supernus&amp;phase=2&amp;draw=2&amp;rank=4\" target=\"_blank\">P302</a>, based on a statistical plan excluding patients with mild IA, should be available next quarter.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525134\" data-linked=\"Supernus Pharma up 10% premarket on updated late-stage SPN-810 results\" data-tweet=\"$SUPN - Supernus Pharma up 10% premarket on updated late-stage SPN-810 results https://seekingalpha.com/news/3525134-supernus-pharma-up-10-premarket-on-updated-late-stage-spnminus-810-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3525134-supernus-pharma-up-10-premarket-on-updated-late-stage-spnminus-810-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525125\" data-ts=\"1575986922\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525125-conn-and-dbi-among-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CONN and DBI among premarket losers</a></h4><ul><li>Conn's (NASDAQ:<a href='https://seekingalpha.com/symbol/CONN' title='Conn&#39;s, Inc.'>CONN</a>) <font color=\"red\">-26%</font> on <a href=\"https://seekingalpha.com/news/3525018-conns-eps-beats-0_07-misses-on-revenue\" target=\"_blank\">Q3 earnings</a>.</li><li>Francesca's Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/FRAN' title='Francesca&#39;s Holdings Corporation'>FRAN</a>) <font color=\"red\">-21%</font> on <a href=\"https://seekingalpha.com/news/3525064-francescas-reports-q3-results\" target=\"_blank\">Q3 earnings</a>.</li><li>Designer Brands (NYSE:<a href='https://seekingalpha.com/symbol/DBI' title='Designer Brands Inc.'>DBI</a>) <font color=\"red\">-18%</font> on <a href=\"https://seekingalpha.com/news/3525032-designer-brands-eps-misses-0_07-beats-on-revenue\" target=\"_blank\">Q3 earnings</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3525125\" data-linked=\"CONN and DBI among premarket losers\" data-tweet=\"$CONN $FRAN $DBI - CONN and DBI among premarket losers https://seekingalpha.com/news/3525125-conn-and-dbi-among-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3525125-conn-and-dbi-among-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:08 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525124\" data-ts=\"1575986793\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNRO\" target=\"_blank\">MNRO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525124-monroplus-1-on-guggenheim-confidence\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Monro +1% on Guggenheim confidence</a></h4><ul> <li>Monro (NASDAQ:<a href='https://seekingalpha.com/symbol/MNRO' title='Monro, Inc.'>MNRO</a>) gains in early trading after catching an upgrade from Guggenheim on its view that the auto retailer can top earnings expectations over the next few years.</li> <li>The firm lifts Monro to a Buy rating from Neutral and assigns a price target of $92 vs. the <a href=\"https://seekingalpha.com/symbol/MNRO/ratings/sell-side-ratings\" target=\"_blank\">average sell-side PT</a> of $73.60.</li> <li>Shares of Monro are <font color=\"green\">up 1.14%</font> premarket to $75.24.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3525124\" data-linked=\"Monro +1% on Guggenheim confidence\" data-tweet=\"$MNRO - Monro +1% on Guggenheim confidence https://seekingalpha.com/news/3525124-monroplus-1-on-guggenheim-confidence?source=tweet\" data-url=\"https://seekingalpha.com/news/3525124-monroplus-1-on-guggenheim-confidence\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:06 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525116\" data-ts=\"1575986391\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FRAN\" target=\"_blank\">FRAN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525116-francescasminus-26-after-tipping-ceo-search\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Francesca&#39;s -26% after tipping CEO search</a></h4><ul> <li>Francesca's (NASDAQ:<a href='https://seekingalpha.com/symbol/FRAN' title='Francesca&#39;s Holdings Corporation'>FRAN</a>) plummets after the company says it hired an executive search firm to start a formal search for a replacement CEO. Investors could be curious about the long delay with an interim CEO having been in the top post since last January.</li> <li>During <a href=\"https://seekingalpha.com/pr/17723157-francesca-s-reports-third-quarter-fiscal-year-2019-financial-results\" target=\"_blank\">Q3</a>, Francesca's saw a 1% increase in comparable sales and gross profit margin improvement of 420 bps off higher merchandise margins.</li> <li>Shares of Francesca's are down <font color=\"red\">26.22%</font> in premarket action on volume of over 71K.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3525064-francescas-reports-q3-results\" target=\"_blank\">Francesca's reports Q3 results</a> (Dec. 10)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3525116\" data-linked=\"Francesca&#39;s -26% after tipping CEO search\" data-tweet=\"$FRAN - Francesca&#39;s -26% after tipping CEO search https://seekingalpha.com/news/3525116-francescasminus-26-after-tipping-ceo-search?source=tweet\" data-url=\"https://seekingalpha.com/news/3525116-francescasminus-26-after-tipping-ceo-search\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525114\" data-ts=\"1575986143\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARAV\" target=\"_blank\">ARAV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525114-cantor-likes-aravive-in-premarket-analyst-action\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cantor likes Aravive in premarket analyst action</a></h4><ul><li>Aravive (NASDAQ:<a href='https://seekingalpha.com/symbol/ARAV' title='Aravive, Inc.'>ARAV</a>) initiated with Overweight rating and $30 (166% upside) price target at Cantor Fitzgerald. Shares up <font color=\"green\">5% </font>premarket.</li><li>Seattle Genetics (NASDAQ:<a href='https://seekingalpha.com/symbol/SGEN' title='Seattle Genetics, Inc.'>SGEN</a>) resumed with Equal Weight rating at Morgan Stanley.</li><li>Avid Bioservices (NASDAQ:<a href='https://seekingalpha.com/symbol/CDMO' title='Avid Bioservices, Inc.'>CDMO</a>) upgraded to Strong Buy at First Analysis.</li><li>X4 Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/XFOR' title='X4 Pharmaceuticals, Inc.'>XFOR</a>) upgraded to Buy with a $20 (64% upside) price target at Citigroup.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525114\" data-linked=\"Cantor likes Aravive in premarket analyst action\" data-tweet=\"$ARAV $SGEN $CDMO - Cantor likes Aravive in premarket analyst action https://seekingalpha.com/news/3525114-cantor-likes-aravive-in-premarket-analyst-action?source=tweet\" data-url=\"https://seekingalpha.com/news/3525114-cantor-likes-aravive-in-premarket-analyst-action\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:55 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525110\" data-ts=\"1575985932\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHD\" target=\"_blank\">CHD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525110-church-dwightminus-2-after-jpmorgan-warning\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Church &amp; Dwight -2% after JPMorgan warning</a></h4><ul> <li>JPMorgan lowers Church &amp; Dwight (NYSE:<a href='https://seekingalpha.com/symbol/CHD' title='Church & Dwight Co., Inc.'>CHD</a>) to an Underweight rating from Neutral on its view consensus estimates are too high.</li> <li>\"We believe some of the company\u2019s recent pricing actions may continue to have volume implications over the next few quarters. With the company\u2019s long-cycle of outperformance and market share gains at risk, we believe the stock will de-rate from its current premium to peers back to the average over the past five years. We also think the most recent acquisitions will prove less accretive to growth as devices/tools (Flawless and Waterpik) are in categories that have less recurrence of purchases or parts re-ordering, and are less scalable against its predominant channels. While we praise CHD\u2019s nimble approach to marketing and execution historically, we believe the next two quarters will remain challenging from a volume perspective, and although management said they will lean more on innovation in 2020, we think it carries higher execution risk.\"</li> <li>The firm lowers its price target to $65 from $74 to factor in a 23.5X earnings multiple vs. 27X prior. The <a href=\"https://seekingalpha.com/symbol/CHD/ratings/sell-side-ratings\" target=\"_blank\">average sell-side PT</a> is $72.03.</li> <li>Shares of Church &amp; Dwight are <font color=\"red\">down 2.41%</font> premarket to $68.65.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3525110\" data-linked=\"Church &amp; Dwight -2% after JPMorgan warning\" data-tweet=\"$CHD - Church &amp; Dwight -2% after JPMorgan warning https://seekingalpha.com/news/3525110-church-dwightminus-2-after-jpmorgan-warning?source=tweet\" data-url=\"https://seekingalpha.com/news/3525110-church-dwightminus-2-after-jpmorgan-warning\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525103\" data-ts=\"1575985203\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CSX\" target=\"_blank\">CSX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525103-csx-dips-after-citi-moves-to-sidelines\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CSX dips after Citi moves to the sidelines</a></h4><ul> <li>Citi lowers CSX (NASDAQ:<a href='https://seekingalpha.com/symbol/CSX' title='CSX Corporation'>CSX</a>) to a Neutral rating from Buy on concerns over revenue growth next year.</li> <li>The firm drops its price target to $75 from $80 to account for the lowered sales expectation. The <a href=\"https://seekingalpha.com/symbol/CSX/ratings/sell-side-ratings?s=csx\" target=\"_blank\">average sell-side PT</a> on CSX is $76.42.</li> <li>Shares of CSX are <font color=\"red\">down 1.25%</font> premarket to $69.53.</li>    </ul><div class=\"tiny-share-widget\" data-id=\"3525103\" data-linked=\"CSX dips after Citi moves to the sidelines\" data-tweet=\"$CSX - CSX dips after Citi moves to the sidelines https://seekingalpha.com/news/3525103-csx-dips-after-citi-moves-to-sidelines?source=tweet\" data-url=\"https://seekingalpha.com/news/3525103-csx-dips-after-citi-moves-to-sidelines\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:40 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525094\" data-ts=\"1575984591\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNY\" target=\"_blank\">SNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525094-sanofis-sutimlimab-successful-in-late-stage-cold-agglutinin-disease-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sanofi&#39;s sutimlimab successful in late-stage cold agglutinin disease study</a></h4><ul><li>A Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03347396?cond=Cold+Agglutinin+Disease&amp;phase=2&amp;draw=2&amp;rank=1\" target=\"_blank\">CARDINAL</a>, evaluating Sanofi's (NASDAQ:<a href='https://seekingalpha.com/symbol/SNY' title='Sanofi'>SNY</a>) sutimlimab (BIVV009) in patients with <a href=\"https://rarediseases.info.nih.gov/diseases/6130/cold-agglutinin-disease\" target=\"_blank\">primary cold agglutinin disease</a> &#40;CAD&#41; <a href=\"https://seekingalpha.com/pr/17723134-sanofi-positive-results-presented-from-pivotal-phase-3-trial-of-sutimlimab-in-people-cold\" target=\"_blank\">met the primary and secondary endpoints</a>. The results were presented at ASH in Orlando.</li><li>The primary efficacy endpoint was the response rate as measured by a composite of an increase in hemoglobin from baseline or reaching a certain hemoglobin level at week 26 and the absence of transfusions from week 5 to 26.</li><li>54% (n=13/24) of subjects met the composite criteria and 63% (n=15/24) achieved hemoglobin levels of at least 12 g/dL (normal range for men and women: 13.5 - 17.5 g/dL and 12.0 - 15.5 g/dL, respectively). 83% (n=20/24) achieved clinically significant improvements in hemoglobin levels.</li><li>On the safety front, 29% (n=7/24) of patients experienced at least one serious adverse event, none considered related to the study drug.</li><li>Sutimlimab is a humanized monoclonal antibody that binds to (<a href=\"https://www.jimmunol.org/content/202/4/1200\" target=\"_blank\">inhibits</a>) a complement-specific serine protease enzyme called C1s that plays a key role in the mechanism of hemolysis in CAD, a rare autoimmune disorder in which the body's immune system destroys red blood cells.</li><li>The company plans to file marketing applications in the near future. The indication has Breakthrough Therapy status in the U.S.</li><li>Shares up <font color=\"green\">4%</font> premarket on modest volume.</li><li>#ASH19</li></ul><div class=\"tiny-share-widget\" data-id=\"3525094\" data-linked=\"Sanofi&#39;s sutimlimab successful in late-stage cold agglutinin disease study\" data-tweet=\"$SNY - Sanofi&#39;s sutimlimab successful in late-stage cold agglutinin disease study https://seekingalpha.com/news/3525094-sanofis-sutimlimab-successful-in-late-stage-cold-agglutinin-disease-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3525094-sanofis-sutimlimab-successful-in-late-stage-cold-agglutinin-disease-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525093\" data-ts=\"1575984524\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ASNA\" target=\"_blank\">ASNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525093-ascena-retailplus-35-after-unexpected-profit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ascena Retail +35% after unexpected profit</a></h4><ul> <li>Ascena Retail (NASDAQ:<a href='https://seekingalpha.com/symbol/ASNA' title='Ascena Retail Group, Inc.'>ASNA</a>) shoots higher in early trading after spilling <a href=\"https://seekingalpha.com/pr/17722594-ascena-retail-group-inc-announces-first-quarter-fiscal-2020-results-reports-income-per-share\" target=\"_blank\">FQ1</a> EPS of $0.18 vs. -$0.09 consensus.</li> <li>Comparable sales were flat during the quarter as drops with the Ann Taylor, Loft and Premium Fashion businesses were offset by gains with Lane Bryant, Plus Fashion, Dressbarn and Value Fashion.</li> <li>Gross margin fell 20 bps to 59.6% of sales during the quarter. The decline in gross margin rate was primarily due to higher promotional activity at the Kids Fashion and Premium Fashion segments.  Those declines were partially offset by increased margins at the Plus Fashion segment, reflecting improved product acceptance and a higher mix of full price selling, and at the Value Fashion segment.</li> <li>Shares of Ascena Retail are <font color=\"green\">up 35.44%</font> to $0.60.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3524924-ascena-retail-group-reports-q1-results\" target=\"_blank\">Ascena Retail Group reports Q1 results</a> (Dec. 9)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3525093\" data-linked=\"Ascena Retail +35% after unexpected profit\" data-tweet=\"$ASNA - Ascena Retail +35% after unexpected profit https://seekingalpha.com/news/3525093-ascena-retailplus-35-after-unexpected-profit?source=tweet\" data-url=\"https://seekingalpha.com/news/3525093-ascena-retailplus-35-after-unexpected-profit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525091\" data-ts=\"1575984123\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MTN\" target=\"_blank\">MTN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525091-vailplus-2-on-positive-update-on-early-skis-season-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vail +2% on positive update on early skis season results</a></h4><ul>  <li>Shares of Vail Resorts (NYSE:<a href='https://seekingalpha.com/symbol/MTN' title='Vail Resorts, Inc.'>MTN</a>) are higher in early action after the company says season pass sales were up 17% from a year ago in terms of dollar value and 22% by the number of passes sold.</li> <li>During the earnings call, Vail management noted the early season experience at resorts has been encouraging with strong conditions across Colorado, Tahoe, and Northeastern resorts. Both Keystone and Vail were said to have benefited from early snow and Vail's recent snowmaking investments, which allowed Keystone to open on October 12 and Vail to open on October 15.</li> <li><a href=\"https://seekingalpha.com/article/4311536-vail-resorts-inc-mtn-ceo-rob-katz-on-q1-2020-results-earnings-call-transcript\" target=\"_blank\">Earnings call transcript</a></li> <li>VAIL <font color=\"green\">+1.59%</font> premarket to $234.50.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3524913-vail-resorts-eps-beats-0_34-beats-on-revenue\" target=\"_blank\">Vail Resorts EPS beats by $0.34, beats on revenue</a> (Dec. 9)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3524917-vail-resorts-posts-fq1-ebitda-loss\" target=\"_blank\">Vail Resorts posts FQ1 EBITDA loss</a> (Dec. 9)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3525091\" data-linked=\"Vail +2% on positive update on early skis season results\" data-tweet=\"$MTN - Vail +2% on positive update on early skis season results https://seekingalpha.com/news/3525091-vailplus-2-on-positive-update-on-early-skis-season-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3525091-vailplus-2-on-positive-update-on-early-skis-season-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525073\" data-ts=\"1575981858\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NFLX\" target=\"_blank\">NFLX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525073-netflixminus-2-after-needham-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Netflix -2% after Needham downgrade</a></h4><ul> <li>Shares of Netflix (NASDAQ:<a href='https://seekingalpha.com/symbol/NFLX' title='Netflix, Inc.'>NFLX</a>) are down in early trading after Needham cuts its rating on the streamer to Underperform from Hold.</li> <li>Needham points to subscriber loss in the U.S. for Netflix. That call varies from the estimates of some other firms of minimal impact of new streaming competition on Netflix in the U.S.</li> <li>NFLX <font color=\"red\">-2.36% </font>premarket to $295.36.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3525073\" data-linked=\"Netflix -2% after Needham downgrade\" data-tweet=\"$NFLX - Netflix -2% after Needham downgrade https://seekingalpha.com/news/3525073-netflixminus-2-after-needham-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3525073-netflixminus-2-after-needham-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>41&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525070\" data-ts=\"1575981548\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/F\" target=\"_blank\">F</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525070-ford-expects-to-cut-losses-in-china-over-next-two-years\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ford expects to cut losses in China over next two years</a></h4><ul> <li>Ford (NYSE:<a href='https://seekingalpha.com/symbol/F' title='Ford Motor Company'>F</a>) says it <a href=\"https://www.reuters.com/article/us-ford-china/ford-to-nearly-halve-its-2018-before-interest-and-taxes-loss-in-china-idUSKBN1YD2JJ\" target=\"_blank\">expects</a> its full year 2019 loss this year in China before interest and taxes are factored in to be about half of what it was a year ago.</li> <li>The automaker expects to cut down its China losses before interest and taxes by almost 50% again in 2020 and see further improvement in 2021.</li> <li>Ford will release Q4 and full-year results on February 4.</li> <li><a href=\"https://seekingalpha.com/filing/4729646\" target=\"_blank\">SEC Form 8-K</a></li> <li>Shares of Ford are <font color=\"red\">down 0.67%</font> in premarket trading to $8.95.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3525070\" data-linked=\"Ford expects to cut losses in China over next two years\" data-tweet=\"$F - Ford expects to cut losses in China over next two years https://seekingalpha.com/news/3525070-ford-expects-to-cut-losses-in-china-over-next-two-years?source=tweet\" data-url=\"https://seekingalpha.com/news/3525070-ford-expects-to-cut-losses-in-china-over-next-two-years\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>46&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525068\" data-ts=\"1575981453\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTON\" target=\"_blank\">PTON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525068-pelotonplus-1-after-keybanc-reiterates-positive-view\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Peloton +1% after KeyBanc reiterates positive view</a></h4><ul> <li>KeyBanc Capital Markets says holiday sales are going well for Peloton Interactive (NASDAQ:<a href='https://seekingalpha.com/symbol/PTON' title='Peloton Interactive, Inc.'>PTON</a>) based off proprietary store checks.</li> <li>The firm isn't the only one who thinks that the Peloton advertising miscue will raise brand awareness.</li> <li>KeyBanc sticks with an Overweight rating on Peloton and a price target of $45 vs. the <a href=\"https://seekingalpha.com/symbol/PTON/ratings/sell-side-ratings\" target=\"_blank\">average sell-side PT</a> of $32.63.</li> <li>Shares of Peloton are <font color=\"green\">up 1.09%</font> premarket to $35.15.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3525068\" data-linked=\"Peloton +1% after KeyBanc reiterates positive view\" data-tweet=\"$PTON - Peloton +1% after KeyBanc reiterates positive view https://seekingalpha.com/news/3525068-pelotonplus-1-after-keybanc-reiterates-positive-view?source=tweet\" data-url=\"https://seekingalpha.com/news/3525068-pelotonplus-1-after-keybanc-reiterates-positive-view\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525057\" data-ts=\"1575980473\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CORV\" target=\"_blank\">CORV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525057-correvio-shares-halted-for-ad-com-review-of-brinavess-for-af\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Correvio shares halted for Ad Com review of Brinavess for AF</a></h4><ul><li>Nasdaq has <a href=\"https://seekingalpha.com/pr/17723107-correvio-stock-trading-halted-today-fda-advisory-committee-meeting-to-discuss-brinavess-for\" target=\"_blank\">suspended trading</a> in Correvio Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/CORV' title='Correvio Pharma Corp.'>CORV</a>) for today's meeting of the FDA's Cardiovascular and Renal Drugs Advisory Committee to review and discuss its application for Brinavess (vernakalant hydrochloride, IV) for the rapid conversion of recent onset atrial fibrillation &#40;AF&#41; in adults.</li><li><a href=\"https://www.fda.gov/advisory-committees/advisory-committee-calendar/december-10-2019-meeting-cardiovascular-and-renal-drugs-advisory-committee-meeting-announcement#event-materials\" target=\"_blank\">Meeting materials</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3525057\" data-linked=\"Correvio shares halted for Ad Com review of Brinavess for AF\" data-tweet=\"$CORV - Correvio shares halted for Ad Com review of Brinavess for AF https://seekingalpha.com/news/3525057-correvio-shares-halted-for-ad-com-review-of-brinavess-for-af?source=tweet\" data-url=\"https://seekingalpha.com/news/3525057-correvio-shares-halted-for-ad-com-review-of-brinavess-for-af\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}